--- Page 1 ---
Metabolic implications 
of the 
Lifewave X39 Patch 
 
Melinda H. Connor, D.D., Ph.D., AMP, FAM 
Caitlin A. Connor, MAcOM, DAOM 
Naran Gombosuren, Ph.D. 
Jens Eickhoff, Ph.D. 
 
 
Introduction 
 
 
This study explores the metabolic implications and physiologic results of wearing 
the Lifewave X39 patch over the period of one week. Measures were taken at baseline, 
24 hours and at 7 days of wearing the patch. A sample of convenience of 15 subjects 
made up of both men and women aged 40-65 were selected to participate in this study. 
Background 
 
The Lifewave X39 patch focuses on stimulating the copper tripeptide GHK- Cu.  
“Copper tripeptide-1(GHK-Cu) is a small protein composed of the three amino acids 
(protein building blocks) glycine, histidine, and lysine combined in a specific geometric 
configuration with the physiologically beneficial mineral. (copper)” (DeHaven, C., 2014)  
This tripeptide was first isolated from human plasma albumin in 1973 by Dr. Loren 
Pickart.  Pickart, noticed differences in the levels of fibrinogen based on age. He 
additionally noticed that these differences stopped when the older liver cells were 
incubated in blood from younger individuals. “In 1977, David Schlesinger of the Harvard 
University Chemistry Department confirmed that the growth modulating peptide isolated 
by Pickart was a glycyl-L-histidyl-L-lysine peptide.”  It is interesting to note that this 
peptide has also been found in saliva, urine, and collagen. Additional research has 
established the strong affinity the GHK peptide has for copper, and exists in two forms, 


--- Page 2 ---
as this was not covered in the initial experiment. These two forms are GHK and GHK-
Cu. It is also important to mention that none of the research around GHK has ever found 
it to cause an issue. (DeHaven, C., 2014)   
The “copper tripeptide-1 belongs to a group of emergency response molecules 
which are released during injury and come to the body’s aid...” (DeHaven, C., 2014)  It is 
naturally released by the body when there is any type of injury to tissue. Research has 
identified that the peptide is used to signal the beginning of the natural repair process. 
This benefit has specifically been documented through research for post-laser or surgical 
wounds, ischemic, burns, skin or hair transplants, and diabetic ulcers. “Diabetic wounds 
healed three times faster in the presence of Copper tripeptide-1. Time to re-
epitheliazation is shortened.” (DeHaven, C., 2014)  The “copper tripeptide-1 has been 
suggested to have a potential therapeutic role in age-related neurodegeneration and 
cognitive decline. It improves axon survival and maintenance of nerves.” (DeHaven, C., 
2014) 
The tripeptide has also been demonstrated to improve tissue remodeling. “It 
increases keratinocyte proliferation and normal collagen synthesis, improves skin 
thickness, skin elasticity and firmness, improves wrinkles, photodamage and uneven 
pigmentation, improves skin clarity, and tightens protective barrier proteins.” (DeHaven, 
C., 2014) This has an impact on both scars and other effects of damage to the skin, and 
natural aging processes. The effects of tissue remodeling also appear to have an impact 
on cancerous cells. “The fact that GHK was able to suppress 70% of genes involved in 
the development of an aggressive metastatic form of colon cancer indicates that GHK is 
capable of the regulation of various biochemical pathways on a gene level and it seems to 


--- Page 3 ---
be resetting the gene activity back to health, which leads to the improvement of tissue 
repair.” (Pickart, L., 2015) 
GHK-Cu also has a demonstrated impact on other organs in the body after they 
have been damaged. “A collaborative study conducted by scientists from Boston 
University, University of Groningen, University of British Columbia, and University of 
Pennsylvania established that the GHK peptide reverses the gene expression signature of 
COPD, which is manifested by emphysema, inflammation, lung tissue destruction, and 
significant reduction of lung capacity.” (Pickart, L., 2015)  It is also important to note 
that “…the level of GHK is about 200 ng/mL(10−7M) at age 20, but declines to 80 
ng/mL by age 60.” (Pickart, L., 2015) This likely explains the increasing effects of aging. 
It would also suggest that increased levels over time of GHK-Cu would have a positive 
effect on both life expectancy and aging.  
Non-transdermal Patch 
 
All X39 patches are sealed so that none of the substances in the patch actually 
penetrate the skin. This allows for consistent patch promotion of the light flow through 
out the time the patch is worn. In this study the initial baseline readings were taken, then 
the X39 patch was applied. The participant will be asked to wear the patch 12 hours each 
day. The participant removed the patch at night and a fresh patch was applied each 
morning prior to 8 am.  The patch was worn for a minimum of 1 hour before the 
additional data measures were taken. Patches were worn for a total of 7 days. Data taking 
with the patch applied was done on day one, day two and day seven. 
 
 


--- Page 4 ---
Phototherapy 
Phototherapy has been defined as “the use of ultraviolet (UV) light for its healing 
effects.” (Kakimoto, C., 2017) Supported by normal electro-dermal skin conductance 
(Becker, (1985), Flick, (2004)), the human body gives off a number of materials 
biochemically including particulate release, gas emission, ultraviolet light, near infrared 
light, and visible spectrum light. The Lifewave patches have been specifically developed 
to reflect this light back onto the skin where the patch has been placed. This then 
stimulates the area of skin, producing improved physiological effects. Variations on 
phototherapy have been used for at least 100 years. In that time there has been little 
evidence of negative side effects. There is a theoretical concern about an increase in 
cancer rates, but “there was no significant association found with basal cell carcinoma, 
squamous cell carcinoma or melanoma.” (Kakimoto, C., 2017) This suggests that this is a 
relatively untapped option for healing with relatively few risks.  
Meridian Implications and Patch placement 
 
The Lifewave patches are placed on specific meridian points to maximize 
effectiveness. The theory of balancing the body based on the Chinese meridian system is 
over 3000 years old.  Current information now maps the meridian system to parts of the 
lymphatic system. The concept of the release of “Qi” on an area of the lymphatic system 
is consistent with the evidence that the body has a variety of electrical-dermal potentials 
across its surface (Becker & Selden, 1985, Flick, 2004) and that acupuncture points are 
(at least in part) strategic conductors of electromagnetic signals (Feinstein, 2010).   
There are two options for patch placement which have been defined for the X39 
patch. The first is a point on the back, also known as GV14, Du-14, or Tao Dao, which 


--- Page 5 ---
may create a few relevant effects. It is a meeting point of the Governing vessel with all of 
the Yang meridians. It is also the Point of the Sea of Qi. All of these mean that point 
would have a direct impact on the Yang meridians of the body, and both generally Qi and 
Yang in the body. It specifically expels wind and firms the exterior, which will help 
prevent illness and reduce shaking. It also clears heat, which would include inflammation 
and redness, which is a common sign of tissue damage. It also works specifically on 
malaria, as well as building any bodily substance that is depleted and pacifies wind. 
(Deadman, P., 2001)  
The second, is a point on the lower abdomen, also known as CV-6, or Qi Hai. 
This point works in a slightly different direction. It fosters Original Qi, builds Qi overall, 
supports the Kidneys and fortifies Yang, rescues collapsed Yang, regulates Qi, and 
harmonizes blood. This means that it helps congenital problems or the general effects of 
aging. It also helps with genital issues, such as impotence, prolapse of the uterus, and 
infertility. It also helps with pain or masses in the abdomen. Between these two points 
most, if not all, of the previously noted impacts of the X39 patch are supported. 
(Deadman, P., 2001) 
This study focused on the metabolic impact of patch usage, with half the 
participants using the CV6 point and half using the GV14 point. 
 
Metabolic Suite 
 
For the purposes of this study the Sabre Sciences HPA2 metabolic suite has been 
selected. The HPA 2 Profile includes both urine and saliva collection. The urine 
evaluates: 5-HTP, Serotonin, Dopamine, Epinephrine, Norepinephrine, GABA, 
Glutamate, Histamine, L-DOPA, Normetanephrine, Metanephrine 


--- Page 6 ---
3-Methoxytyramine. The  saliva evaluates: Cortisol and DHEA. Several additional 
measures have been added to the HPA2 suite, Glutathione, and a cysteine to cystine ratio 
will also be tested using the urine sample. Three measures will be taken: baseline, 24 
hours and 7days.  (Sabre Sciences Laboratory, http://www.sabresciences.com/ ):  
 
Metabolic testing consisted of one 10am urine taken at baseline/day one, day two 
and day seven.  Saliva Testing consisted of a six swabs taken in one day at baseline/day 
one, day two and seven. Subjects self-administered the swab under the supervision of Dr. 
Connor when in the laboratory, which was then placed back in the shipping container and 
labeled with the subject number. Samples were kept in the freezer at -20F and were 
shipped with ice by UPS to the Sabre Science lab in Carlesbad, CA on a daily basis. 
Physiology Suite 
 
 
All study participants had the following physiological testing done at base line, 24 
hours and 7 days: Six minute recordings of EKG, pulse, respiration, heart rate variability 
(HRV), temp, blood volume pulse, galvanic skin response, and 2 EMG (muscle) leads 
(one on each shoulder area). At baseline testing, participants were checked for any 
allergic reactions to the adhesive patches. Allergic reactions to physiological test patches 
happen at a rate of 1:100,000 and if an allergic reaction was discovered participants 
would be referred to the local urgent care for treatment and then dropped from the study. 
No participats in this study had an adverse event of any type. Fresh adhesive patches 
were used for each person tested. Adhesive patches are disposed of in bio hazard 
containers after use.  
 
 
 
 


--- Page 7 ---
Questionnaires 
 
 
A series of questionnaires were administered to support the metabolic findings. 
 
Marlowe Crowne 
 
The Marlowe Crowne is a 13 Item true/false short form that is a measure of 
subjects tendencies to give answers that they may perceive are desired by the interviewer 
and/or reflect perceived positive social norms. This variable can produce inaccurate or 
misleading findings unless properly controlled for in statistical analysis. Estimated 
completion time 2 minutes. This instrument was normed by Renyolds in 1982. 
 
McGill Pain Scale 
 
This scale is comprised of three sections regarding a subject’s pain. Section 
number one asks, “What Does Your Pain Feel Like?” and then lists 20 descriptive 
categories that are numerically rated as 1 – 5. Section number two asks, “How Does Your 
Pain Change with Time?”. The first question asks the subject to describe the pattern of 
their pain; and this is followed by 22 descriptive terms regarding their effects on 
increasing or decreasing pain. The third section reflects upon the strength of the pain and 
has six questions that give a context and comparison to the current pain compared to 
other types of pain suffered in the past. Again this section is ranked numerically 1-5, with 
one being mild and five being excruciating. 
Pittsburg Sleep Quality Index 
 
This scale is comprised of a mix of quantitative questions and five likert scale 
questions 0-3. It explores the type and quality of sleep experienced by an individual over 
the past month. It was normed by Cole et al. (2006). 
 


--- Page 8 ---
Arizona Integrative Outcome Scale, Visual Analogue Scale (AIOS-VAS)  
for Vitality 
The AIOS- VAS rates subject’s “overall sense of well-being and vitality” over the 
past 24 hours, using a 100mm one-line visual analogue scale. This instrument was 
normed by Bell in 2003. 
Profile of Mood States (POMS) 
The POMS is a 37-item 5 factor scale which is a basic measure of affective state 
in several dimensions including vigor, mood, anxiety and depression.  8 minutes 
maximum completion time. It was normed by McNair et al., 1971/1981; Shacham, 1983. 
WAS III   
A subsection of the WAS III will be used to determine level of short and long 
term memory and if there is an improvement in memory from baseline to 7 days. 
 Statistical Analysis 
 
Data from questionnaires were collected on standard answer sheets and scored. Then the 
data points were entered into an excel spread sheet for statistical evaluation. Standardized tests 
were scored and reviewed for data trends and significant results.  All questionnaires parameters 
were summarized in terms of means and standard deviation, stratified by assessment time point. 
Changes between assessment time points were evaluated using a paired t-test or nonparametric 
Wilcoxon Signed Rank test.  All physiology parameters were summarized in terms of means and 
standard deviation, stratified and across the 6 study epochs.  Changes from pre-to post patch 
administration were evaluated using a paired t-test. Normal probability plots were examined to 
verify the distribution assumptions. All reported P-values are two-sided and P<0.05 was used to 
define statistical significance. All metabolic parameters were summarized in terms of means and 


--- Page 9 ---
standard deviation, stratified by assessment time point. Changes from day 1 (pre-patch) to day 2, 
day 2  to day 7, and day 1 to day 7 were evaluated using a paired t-test or nonparametric 
Wilcoxon Signed Rank test. Cortisol levels were obtained at 8am, 12pm, 4pm, 8pm and 12am. 
DHEAS levels were collected at 8am, 8pm and 12am. The area under the curve (AUC) for 
Cortisol and DHEAS levels over the data collection periods were calculated using the trapezoid 
rule. AUC levels were summarized in terms of means and standard deviations, stratified by 
assessment time point. Changes between assessment time points were evaluated using a paired t-
test or Wilcoxon signed rank test. 
Results 
 
The complete data results of the testing are found in Appendix A. Significant 
results of the Lifewave X39 patch testing are as follows: 
Table 1: Demographics (N=15) 
 
N (%) 
Gender 
Female 
Male 
 
10 (67%) 
5 (33%) 
Age (yrs), means ± 
SD 
61.9 ± 9.3 
 
Important Questionnaire Outcomes 
• Marlowe-Crowne consistent 
• AIOS-VAS 
• WAIS III 
• Profile of Mood States (POMS) No change 
• Modified PSQI 
• 
McGill Pain Instrument No change 
 
Table 2: Summary of Marlowe-Crowne instrument scores, stratified by day 
Day 
N 
Mean 
SD 
1 
15 
16.0 
2.1 
7 
15 
15.5 
2.4 
 


--- Page 10 ---
Table 3: Changes in  Marlowe-Crowne instrument scores from day 1 to day 7 
 
Mean Change SD 
p-value 
Change from day 1 to day 7 
-0.47 
0.2 
0.4614 
 
 
Table 4: Summary of AIOS-VAS instrument scores, stratified by assessment time point 
Time 
N 
Mean 
SD 
Consent 
15 
62.7 
22.8 
1.2 
14 
67.1 
22.8 
2 
14 
71.1 
27.3 
6 
15 
78.0 
23.1 
 
Table 5: Changes in AIOS-VAS instrument scores from Consent to 1.2, Consent to day 2, and Consent to day 7 
assessments  
 
Mean Change 
SD 
p-value 
Change from 1.1 to 2 
7.6 
15.3 
0.0877 
Change from 1.1 to 7 
15.3 
20.6 
0.0151 
 
 
Table 6: Summary of WAISIII instrument scores, stratified by assessment time point 
Time 
Outcome 
N 
Mean 
SD 
Day 1 
# Short 
# Mid 
# Long 
15 
15 
15 
6.2 
5.3 
5.1 
1.9 
2.3 
2.3 
Day 7 
# Short 
# Mid 
# Long 
15 
15 
15 
7.3 
6.1 
6.1 
2.3 
2.9 
3.1 
 
Table7: Changes in WAISIII instrument scores from day 1 to day 7  
 
Outcome 
Mean Change 
SD 
p-value 
Change from Day 1 to Day 7 
# Short 
# Mid 
# Long 
1.1 
0.8 
1.1 
2.4 
2.9 
3.2 
0.0872 
0.3008 
0.2170 
 
Table8: Summary of modified PSQI instrument total scores, stratified by assessment time point 
Time 
N 
Mean 
SD 
Day 1 
11 
6.7 
2.8 
Day 2 
11 
5.2 
2.7 
Day 7 
7 
4.6 
2.9 
 
Table 9: Changes in modified PSQI instrument scores from day 1 to day 2 and from day 1 to day 7  
 
Mean Change 
SD 
p-value 


--- Page 11 ---
Change from Day 1 to Day 2 
-1.0 
1.3 
0.0676 
Change from Day 1 to Day 7 
-3.0 
2.9 
0.0522 
 
 
There were no significant changes in the POMs and the McGill pain scores from the 
baseline (pre-patch) assessment.  
 
 
Important Metabolic Outcomes 
Table 10: Change from day 1 (pre-patch) to day 2, day 2 to day 7, and day 1 (pre-patch) to day 7 
Marker 
Change 
Mean 
Change 
SD 
p-value 
Ala 
Day 1 to Day 2 
-20.17 
36.89 
0.0526 
Cys 
Day 2 to Day 7 
-16.07 
23.86 
0.0206 
E 
Day 1 to Day 2 
-2.09 
3.08 
0.0197 
E 
Day 2 to Day 7 
1.59 
2.94 
0.0552 
GABA 
Day 1 to Day 7 
-0.73 
1.50 
0.0818 
Glu 
Day 2 to Day 7 
-3.82 
6.73 
0.0453 
Glu 
Day 1 to Day 7 
-5.82 
10.37 
0.0475 
Gly 
Day 1 to Day 2 
-72.54 117.73 
0.0317 
HCys2 
Day 1 to Day 2 
0.35 
0.55 
0.0296 
His 
Day 1 to Day 2 
-46.32 
75.35 
0.0320 
His 
Day 1 to Day 7 
-46.64 
49.35 
0.0026 
Hist 
Day 1 to Day 2 
-9.24 
20.20 
0.0981 
Hlys 
Day 1 to Day 7 
-0.80 
1.75 
0.0992 
Leu 
Day 1 to Day 2 
-4.84 
7.84 
0.0313 
NorM 
Day 2 to Day 7 
-13.06 
23.32 
0.0479 
PEA 
Day 1 to Day 7 
-0.59 
1.12 
0.0589 
Phe 
Day 2 to Day 7 
6.33 
10.94 
0.0418 
Ratio 
Day 1 to Day 2 
-0.71 
1.40 
0.0700 
Trp 
Day 2 to Day 7 
-10.81 
18.55 
0.0406 
a-amino 
Day 2 to Day 7 
-5.29 
7.79 
0.0198 
a-amino 
Day 1 to Day 7 
-8.90 
13.79 
0.0256 
 
Important Physiology Outcomes 
 
Table 11: Change from pre-patch to last-patch  (day 7) of HF, LF/HF NN50, PNN50, 
Power, RMSSD, and VLF , stratified by Epoch (1-6) 
Source 
Outcome Epoch 
Mean 
Change 
SD 
p-value 
A_EKG SDNN 
2 
-42.89 
82.71 
0.06430 


--- Page 12 ---
B_BVP 
HF 
5 
-1085.13 
2038.55 
0.05830 
B_BVP 
NN50 
1 
-3.13 
5.34 
0.03950 
B_BVP 
NN50 
2 
-2.13 
4.12 
0.06470 
B_BVP 
NN50 
3 
-1.73 
2.89 
0.03580 
B_BVP 
NN50 
5 
-2.73 
3.03 
0.00360 
B_BVP 
PNN50 
1 
-0.05 
0.08 
0.03820 
B_BVP 
PNN50 
2 
-0.03 
0.07 
0.06880 
B_BVP 
PNN50 
3 
-0.03 
0.04 
0.04290 
B_BVP 
PNN50 
5 
-0.04 
0.04 
0.00360 
B_BVP 
RMSSD 
5 
-21.13 
36.49 
0.04160 
B_BVP 
SDNN 
5 
-19.42 
27.08 
0.01480 
B_BVP 
VLF 
5 
-382.47 
426.65 
0.00370 
 
 
Table 12: Change from pre-patch to last-patch  (day 7) of HF, LF/HF NN50, PNN50, 
Power, RMSSD, and VLF , across all 6 Epochs 
Source 
Outcome 
Mean 
Change 
SD 
p-
value 
A_EKG HF 
-1115.01 
28492.47 
0.7113 
A_EKG LF 
14424.43 
104293.22 
0.1929 
A_EKG LF/HF 
0.28 
1.31 
0.0487 
B_BVP 
HF 
-786.72 
3852.92 
0.0559 
B_BVP 
LF 
205.48 
4414.61 
0.6599 
B_BVP 
LF/HF 
-0.08 
5.93 
0.9004 
B_BVP 
NN50 
-1.96 
3.80 <.0001 
B_BVP 
PNN50 
-0.03 
0.06 <.0001 
B_BVP 
RMSSD 
-21.78 
76.48 
0.0083 
B_BVP 
SDNN 
-18.60 
63.27 
0.0065 
 
Table 13: Change from pre-patch to last-patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate for Average,Mode,and Area, stratified by Epoch (1-6) 
Source 
Outcome 
Epoch 
Mean 
Change 
SD 
p-
value 
BVP_HR 
1:Average 
2 
4.51 
7.83 
0.0426 
BVP_HR_Max_Min 1:Average 
5 
-2.23 
3.13 
0.0153 
BVP_HR_Max_Min 2:Mode 
1 
-1.18 
2.17 
0.0533 
BVP_HR_Max_Min 2:Mode 
2 
-0.73 
1.57 
0.0917 
EKG_HR_Max_Min 2:Mode 
6 
-33.34 
67.42 
0.0871 
Resp_Rate 
2:Mode 
1 
1.92 
4.03 
0.0868 
 
 


--- Page 13 ---
Table 14: Change from pre-patch to last-patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate for Average, Mode,and Area, across all 6 Epochs 
Source 
Outcome 
Mean 
Change 
SD 
p-value 
BVP_HR 
1:Average 
2.54 
8.31 
0.0047 
BVP_HR 
2:Mode 
2.31 
9.60 
0.0249 
BVP_HR_Max_Min 1:Average 
-1.67 
5.50 
0.0049 
C_EMG 
1:Average 
-39.44 
124.62 
0.0035 
C_EMG 
2:Mode 
-38.45 
128.72 
0.0057 
C_EMG 
3:Area 
-2366.63 
7477.30 
0.0035 
 
Discussion 
 
It is important to recognize that this was both a sample of convience and a short-
term study with a small sample size. However,  
Summary 
 
 
This study, as designed, is fairly comprehensive in nature, exploring the metabolic 
and physiologic aspects of the Lifewave X39 patch. In addition the questionnaires which 
were administered cover a range of previously reported experiences with the X39 
patches. These include quality of sleep improvement, memory improvement, feelings of 
vitality, reduction of pain and inflammation, and an overall sense of well-being. This 
study provides a short term picture of the lived experience of participants who are 
wearing the Lifewave X39 Phase III patch daily.  
The data results of improvement in blood pressure, 17 statistically significant 
amino acid changes over the 7 days, improvement in sleep levels, improvement in short 
term memory, improvement in reported feelings of vitality and consistancy in reporting 
across the study suggest that further research with a larger sample size be done and 
confirm the previously reported annecdotal responses in the testing of earlier subjects. 
The Lifewave X39 patch shows clear, significant metabolic changes over the course of 


--- Page 14 ---
one week which should be explored over longer periods of time in future studies so that a 
better understanding of the comprehensive nature and effects of the phototherapy 
produced by this patch may be demonstrated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


--- Page 15 ---
References 
 
Becker, R., Selden, G., “The Body Electric”, William Morrow Pub., New York, NY, 
1985. 
 
Deadman, P., Al-Khafaji, M., Baker, K. (2001) A Manual of Acupuncture. Eastland 
Press. 1240 Activity Dr., #D Vista, CA, 92083.  
 
DeHaven, C., (2014) Copper Tripeptide-1. Science of Skincare.  
 
Feinstein, D., “Rapid Treatment of PTSD: Why Psychological Exposure with Acupoint 
Tapping May Be Effective”, Psychotherapy: Theory, Research, Practice, Training. 47(3), 
385-402, 2010, American Psychological Association. 
 
Flick, A. B., “Silver and Wound Healing”, CAM Research Symposium, Hershey Medical 
School, Hershey PA, July 2004.  
 
Geo Peptides Staff. (2015) What are Copper Peptides? Retrieved August 5, 2018. 
https://www.geopeptides.com/copperpep.html 
 
Kakimoto, C., (2017) What is phototherapy, and how does it work? 
https://www.dermatologistoncall.com/blog/what-is-phototherapy-and-how-does-it-work/ 
 
Pickart, L., Vasquez-Soltero, J., Margolina, A. (2015) GHK Peptide as a Natural 
Modulator of Multiple Cellular Pathways in Skin Regeneration. Hindawi Publishing 
Corporation BioMed Research International Volume 2015, Article ID 648108, 7 pages 
http://dx.doi.org/10.1155/2015/648108.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


--- Page 16 ---
Appendix A: Complete Statistical Results 
 
Statistical Analysis Report 
 
GHK- CU Study – Questionnaire Data 
 
Table 1: Demographics (N=15) ................................................................................................................... 17 
Table 2: Summary of Marlowe-Crowne instrument scores, stratified by day ........................................... 17 
Table 3: Changes in  Marlowe-Crowne instrument scores from day 1 to day 7 ........................................ 17 
Table 4: Summary of POMS instrument scores, stratified by assessment time point ............................... 17 
Table 5: Changes in POMS instrument scores from 1.1 to 1.2, 1.1 to 2, and 1.1 to 7 assessment 
time points ................................................................................................................................................. 17 
Table 6: Summary of AIOS-VAS instrument scores, stratified by assessment time point ......................... 17 
Table 7: Changes in AIOS-VAS instrument scores from Consent to 1.2, Consent to 2, and Consent 
to 7 assessments ........................................................................................................................................ 18 
Table 8: Summary of WAISIII instrument scores, stratified by assessment time point ............................. 18 
Table 9: Changes in WAISIII instrument scores from day 1 to day 7 .......................................................... 18 
Table 10: Summary of PSQI instrument total scores, stratified by assessment time point ....................... 18 
Table 11: Changes in PSQI instrument scores from day 1 to day 7 ............................................................ 18 
Table 12: Summary of modified PSQI instrument total scores, stratified by assessment time 
point ........................................................................................................................................................... 18 
Table 13: Changes in modified PSQI instrument scores from day 1 to day 2 and from day 1 to day 
7 .................................................................................................................................................................. 18 
Table 14: Summary of modified McGill total pain  scores, stratified by assessment time point ............... 19 
Table 15: Changes in modified McGill  total pain scores from day 1 to day 2 and from day 1 to 
day 7 ........................................................................................................................................................... 19 
 
Study Design: Single arm study with 2 – 4 assessment time points.  
 
Sample Size:  N=15 
 
Statistical Methods: All physio parameters were summarized in terms of means and 
standard deviation, stratified by assessment time point. Changes between assessment time 
points were evaluated using a paired t-test or nonparametric Wilcoxon Signed Rank test.  
 
Questionnaire Outcomes 
• Marlowe-Crowne 
• AIOS-VAS 
• WAIS III 
• Profile of Mood States (POMS) 
• Pittsburgh Sleep Quality Index (PSQI) 
• Modified PSQI 
• McGill Pain Instrument 
 


--- Page 17 ---
 
 
Table 4: Demographics (N=15) 
 
N (%) 
Gender 
Female 
Male 
 
10 (67%) 
5 (33%) 
Age (yrs), means ± 
SD 
61.9 ± 9.3 
 
Table 5: Summary of Marlowe-Crowne instrument scores, stratified by day 
Day 
N 
Mean 
SD 
1 
15 
16.0 
2.1 
7 
15 
15.5 
2.4 
 
Table 6: Changes in  Marlowe-Crowne instrument scores from day 1 to day 7 
 
Mean Change SD 
p-value 
Change from day 1 to day 7 
-0.47 
0.2 
0.4614 
 
Table 7: Summary of POMS instrument scores, stratified by assessment time point 
Time 
N 
Mean 
SD 
1.1 
15 
28.4 
19.3 
1.2 
14 
29.3 
20.6 
2 
13 
30.6 
20.0 
7 
14 
27.2 
19.2 
 
Table 8: Changes in POMS instrument scores from 1.1 to 1.2, 1.1 to 2, and 1.1 to 7 assessment time points 
 
Mean Change SD 
p-value 
Change from 1.1 to 1.2 
4.4 
11.2 
0.1622 
Change from 1.1 to 2 
4.4 
16.2 
0.3490 
Change from 1.1 to 7 
1.2 
19.2 
0.8162 
 
Table 9: Summary of AIOS-VAS instrument scores, stratified by assessment time point 
Time 
N 
Mean 
SD 
Consent 
15 
62.7 
22.8 
1.2 
14 
67.1 
22.8 
2 
14 
71.1 
27.3 
7 
15 
78.0 
23.1 
 
 
 
 


--- Page 18 ---
Table 10: Changes in AIOS-VAS instrument scores from Consent to 1.2, Consent to 2, and Consent to day 7 assessments  
 
Mean Change 
SD 
p-value 
Change from 1.1 to 1.2 
2.6 
12.8 
0.3146 
Change from 1.1 to 2 
7.6 
15.3 
0.0877 
Change from 1.1 to 7 
15.3 
20.6 
0.0151 
 
Table 11: Summary of WAISIII instrument scores, stratified by assessment time point 
Time 
Outcome 
N 
Mean 
SD 
Day 1 
# Short 
# Mid 
# Long 
15 
15 
15 
6.2 
5.3 
5.1 
1.9 
2.3 
2.3 
Day 7 
# Short 
# Mid 
# Long 
15 
15 
15 
7.3 
6.1 
6.1 
2.3 
2.9 
3.1 
 
Table 12: Changes in WAISIII instrument scores from day 1 to day 7  
 
Outcome 
Mean Change 
SD 
p-value 
Change from Day 1 to Day 7 
# Short 
# Mid 
# Long 
1.1 
0.8 
1.1 
2.4 
2.9 
3.2 
0.0872 
0.3008 
0.2170 
 
Table 13: Summary of PSQI instrument total scores, stratified by assessment time point 
Time 
N 
Mean 
SD 
Day 1 
14 
6.3 
2.8 
Day 7 
11 
5.3 
2.5 
 
Table 14: Changes in PSQI instrument scores from day 1 to day 7  
 
Mean Change 
SD 
p-value 
Change from Day 1 to Day 7 
-0.4 
1.6 
0.5152 
 
Table 15: Summary of modified PSQI instrument total scores, stratified by assessment time point 
Time 
N 
Mean 
SD 
Day 1 
11 
6.7 
2.8 
Day 2 
11 
5.2 
2.7 
Day 7 
7 
4.6 
2.9 
 
Table 16: Changes in modified PSQI instrument scores from day 1 to day 2 and from day 1 to day 7  
 
Mean Change 
SD 
p-value 
Change from day 1 to day 2 
-1.0 
1.3 
0.0676 
Change from day 1 to day 7 
-3.0 
2.9 
0.0522 
 


--- Page 19 ---
Table 17: Summary of modified McGill total pain  scores, stratified by assessment time point 
Time 
N 
Mean 
SD 
Day 1.1 15 
6.2 
6.7 
Day 1.2 15 
9.2 
16.1 
Day 2 
15 
5.9 
9.8 
Day 7 
15 
6.1 
9.0 
 
Table 18: Changes in modified McGill  total pain scores from day 1 to day 2 and from day 1 to day 7  
 
Mean Change 
SD 
p-value 
Change from Day 1.1 to Day 
1.2 
3.0 
16.9 
0.8867 
Change from Day 1.1 to Day 
2 
-0.3 
9.5 
0.7480 
Change from Day 1.1 to Day 
7 
-0.1 
7.7 
0.6328 
 
 
There are no changes in the McGill pain scores from the baseline (pre-patch) assessment.  
 
GHK- CU Study – Physio Data 
 
Table 1: Summary statistics for pre- vs. Last-patch (day 7) of HF, LF/HF NN50, PNN50, Power, 
RMSSD, and VLF , stratified by Epoch (1-6) ................................................................................................ 20 
Table 2: Change from pre-patch to Last-patch  (day 7) of HF, LF/HF NN50, PNN50, Power, 
RMSSD, and VLF , stratified by Epoch (1-6) ................................................................................................ 23 
Table 3: Summary statistics for pre- vs. Last patch (day 7) of HF, LF/HF NN50, PNN50, Power, 
RMSSD, and VLF , across all 6 Epochs ......................................................................................................... 25 
Table 4: Change from pre-patch to Last-patch  (day 7) of HF, LF/HF NN50, PNN50, Power, 
RMSSD, and VLF , across all 6 Epochs ......................................................................................................... 26 
Table 5: Summary statistics for pre- vs. Last patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate  for all distribution characteristics outcomes, stratified by 
Epoch (1-6) ................................................................................................................................................. 27 
Table 6: Change from pre-patch to Last patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate for Average,Mode,and Area, stratified by Epoch (1-6) ..................... 34 
Table 7: Summary statistics for pre- vs. Last patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate  for all distribution characteristics outcomes, across all 6 
epochs ........................................................................................................................................................ 37 
Table 8: Change from pre-patch to Last patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate for Average, Mode,and Area, across all 6 Epochs ............................. 38 
 
 
 


--- Page 20 ---
Study Design: Pre-post study comparing physio outcome measures before patch vs. last 
(day 7) patch administration. 
 
Sample Size:  N=15 
 
 
Statistical Methods: All physio parameters were summarized in terms of means and 
standard deviation, stratified and across the 6 study epochs.  Changes from pre-to post 
patch administration were evaluated using a paired t-test. Normal probability plots were 
examined to verify the distribution assumptions. All reported P-values are two-sided and 
P<0.05 was used to define statistical significance.  
 
 
Table 19: Summary statistics for pre- vs. Last patch (day 7) of HF, LF/HF NN50, PNN50, 
Power, RMSSD, and VLF , stratified by Epoch (1-6) 
 
 
 
Pre-Patch 
Last-Patch (Day 7) 
Source 
Outcome Epoch 
Mean 
SD 
Mean 
SD 
A_EKG HF 
1 
14818.66 
9397.29 
17973.25 
27036.86 
A_EKG HF 
2 
19618.35 
13617.93 
15433.62 
16379.32 
A_EKG HF 
3 
18536.86 
14170.61 
24555.99 
37015.79 
A_EKG HF 
4 
22390.90 
16673.95 
25806.19 
21887.15 
A_EKG HF 
5 
29227.28 
18814.59 
24136.17 
20423.67 
A_EKG HF 
6 
40386.93 
25806.00 
28767.37 
22120.55 
A_EKG LF 
1 
13122.89 
14872.21 
56825.53 
186770.11 
A_EKG LF 
2 
19743.73 
32193.75 
22908.82 
49147.72 
A_EKG LF 
3 
8202.70 
6462.20 
17442.07 
33209.36 
A_EKG LF 
4 
10094.09 
10374.86 
38185.46 
103669.27 
A_EKG LF 
5 
9950.67 
8720.13 
13949.08 
22320.38 
A_EKG LF 
6 
43733.30 
91322.00 
39360.51 
88028.98 
A_EKG LF/HF 
1 
0.81 
0.61 
1.31 
1.57 
A_EKG LF/HF 
2 
0.79 
0.70 
1.01 
0.90 
A_EKG LF/HF 
3 
0.52 
0.38 
0.62 
0.28 
A_EKG LF/HF 
4 
0.52 
0.36 
1.06 
1.54 
A_EKG LF/HF 
5 
0.32 
0.14 
0.47 
0.37 
A_EKG LF/HF 
6 
0.98 
1.46 
1.08 
1.02 
A_EKG NN50 
1 
43.07 
5.18 
41.20 
6.66 
A_EKG NN50 
2 
40.00 
3.78 
42.40 
5.62 
A_EKG NN50 
3 
39.73 
4.95 
39.60 
5.96 
A_EKG NN50 
4 
36.87 
5.26 
38.73 
6.17 
A_EKG NN50 
5 
36.27 
4.73 
38.27 
4.51 
A_EKG NN50 
6 
33.50 
3.55 
34.73 
4.01 
A_EKG PNN50 
1 
0.43 
0.03 
0.42 
0.03 


--- Page 21 ---
A_EKG PNN50 
2 
0.42 
0.03 
0.43 
0.03 
A_EKG PNN50 
3 
0.44 
0.04 
0.44 
0.03 
A_EKG PNN50 
4 
0.44 
0.03 
0.45 
0.04 
A_EKG PNN50 
5 
0.45 
0.03 
0.45 
0.03 
A_EKG PNN50 
6 
0.45 
0.03 
0.44 
0.04 
A_EKG Power 
1 
34860.17 
32520.80 
86493.20 
248715.39 
A_EKG Power 
2 
46274.43 
55655.64 
44593.55 
74597.54 
A_EKG Power 
3 
29563.30 
19470.34 
50064.10 
89856.45 
A_EKG Power 
4 
34334.22 
26054.82 
96776.73 
225900.85 
A_EKG Power 
5 
44102.87 
30199.38 
41466.28 
43405.32 
A_EKG Power 
6 
102250.40 
144643.37 
101064.63 
209062.72 
A_EKG RMSSD 
1 
437.24 
133.90 
461.26 
271.09 
A_EKG RMSSD 
2 
475.06 
123.75 
427.67 
145.70 
A_EKG RMSSD 
3 
510.85 
157.72 
528.37 
234.82 
A_EKG RMSSD 
4 
562.71 
162.39 
564.50 
170.37 
A_EKG RMSSD 
5 
619.63 
144.43 
555.78 
167.73 
A_EKG RMSSD 
6 
684.76 
166.62 
630.29 
146.81 
A_EKG SDNN 
1 
301.56 
92.65 
329.64 
218.09 
A_EKG SDNN 
2 
332.29 
83.30 
289.39 
99.00 
A_EKG SDNN 
3 
339.39 
98.53 
360.14 
177.10 
A_EKG SDNN 
4 
376.69 
108.60 
382.27 
129.24 
A_EKG SDNN 
5 
410.20 
94.19 
377.77 
117.90 
A_EKG SDNN 
6 
481.73 
118.18 
430.35 
93.09 
A_EKG VLF 
1 
6918.61 
16050.31 
11694.41 
36194.08 
A_EKG VLF 
2 
6912.34 
12947.88 
6251.11 
13237.60 
A_EKG VLF 
3 
2823.74 
2898.34 
8066.03 
20471.14 
A_EKG VLF 
4 
1849.23 
1976.73 
32785.09 
109783.63 
A_EKG VLF 
5 
4924.92 
5852.22 
3381.04 
4844.60 
A_EKG VLF 
6 
18130.17 
44250.75 
32936.76 
103944.26 
B_BVP 
HF 
1 
1597.97 
5153.98 
1478.97 
4384.89 
B_BVP 
HF 
2 
3709.23 
7997.67 
963.81 
2638.35 
B_BVP 
HF 
3 
1213.70 
3841.98 
817.30 
2292.51 
B_BVP 
HF 
4 
1191.28 
3220.91 
1731.82 
5853.33 
B_BVP 
HF 
5 
1788.10 
4174.04 
702.97 
2473.38 
B_BVP 
HF 
6 
2699.85 
6288.95 
1622.39 
3902.76 
B_BVP 
LF 
1 
586.06 
1059.94 
1147.30 
3098.88 
B_BVP 
LF 
2 
2868.95 
6006.49 
1935.19 
6356.28 
B_BVP 
LF 
3 
1046.10 
3120.94 
1285.88 
3993.02 
B_BVP 
LF 
4 
885.25 
1525.61 
790.12 
2046.57 
B_BVP 
LF 
5 
969.28 
1348.37 
1426.88 
4933.93 
B_BVP 
LF 
6 
953.94 
1637.05 
1923.23 
4178.71 


--- Page 22 ---
B_BVP 
LF/HF 
1 
1.93 
2.34 
2.74 
2.83 
B_BVP 
LF/HF 
2 
4.50 
8.23 
4.21 
3.17 
B_BVP 
LF/HF 
3 
3.37 
3.92 
4.08 
4.33 
B_BVP 
LF/HF 
4 
5.20 
6.14 
4.15 
4.06 
B_BVP 
LF/HF 
5 
3.88 
4.17 
3.30 
2.54 
B_BVP 
LF/HF 
6 
3.52 
5.70 
3.33 
2.49 
B_BVP 
NN50 
1 
6.27 
6.98 
3.13 
4.22 
B_BVP 
NN50 
2 
5.20 
6.55 
3.07 
4.04 
B_BVP 
NN50 
3 
4.60 
5.41 
2.87 
3.83 
B_BVP 
NN50 
4 
3.67 
5.52 
3.00 
4.55 
B_BVP 
NN50 
5 
5.20 
5.54 
2.47 
4.16 
B_BVP 
NN50 
6 
4.07 
5.28 
2.87 
4.09 
B_BVP 
PNN50 
1 
0.09 
0.11 
0.04 
0.06 
B_BVP 
PNN50 
2 
0.08 
0.10 
0.04 
0.06 
B_BVP 
PNN50 
3 
0.06 
0.08 
0.04 
0.05 
B_BVP 
PNN50 
4 
0.05 
0.08 
0.04 
0.06 
B_BVP 
PNN50 
5 
0.07 
0.08 
0.03 
0.05 
B_BVP 
PNN50 
6 
0.06 
0.08 
0.04 
0.05 
B_BVP 
Power 
1 
2382.37 
6155.15 
2928.16 
7928.99 
B_BVP 
Power 
2 
11457.90 
30247.47 
3129.69 
8971.19 
B_BVP 
Power 
3 
2584.70 
7538.66 
2370.40 
6454.10 
B_BVP 
Power 
4 
2478.29 
4909.61 
2786.08 
8202.62 
B_BVP 
Power 
5 
3199.89 
5488.39 
2189.90 
7450.55 
B_BVP 
Power 
6 
4197.62 
7790.39 
4112.00 
8798.95 
B_BVP 
RMSSD 
1 
79.97 
88.94 
62.61 
86.83 
B_BVP 
RMSSD 
2 
100.03 
147.13 
54.72 
90.07 
B_BVP 
RMSSD 
3 
70.34 
77.13 
50.22 
76.08 
B_BVP 
RMSSD 
4 
56.02 
77.65 
52.32 
87.82 
B_BVP 
RMSSD 
5 
67.67 
76.84 
46.55 
79.93 
B_BVP 
RMSSD 
6 
76.44 
94.67 
57.40 
83.28 
B_BVP 
SDNN 
1 
68.99 
63.28 
54.11 
64.74 
B_BVP 
SDNN 
2 
91.37 
124.34 
54.69 
69.80 
B_BVP 
SDNN 
3 
65.83 
51.38 
50.94 
57.78 
B_BVP 
SDNN 
4 
60.53 
54.55 
54.57 
68.48 
B_BVP 
SDNN 
5 
64.02 
53.42 
44.60 
60.89 
B_BVP 
SDNN 
6 
71.61 
66.03 
54.82 
66.16 
B_BVP 
VLF 
1 
198.34 
159.61 
301.89 
532.47 
B_BVP 
VLF 
2 
4879.73 
16900.51 
230.69 
438.64 
B_BVP 
VLF 
3 
324.89 
614.07 
267.22 
326.91 
B_BVP 
VLF 
4 
401.77 
684.71 
264.15 
350.31 
B_BVP 
VLF 
5 
442.51 
464.44 
60.05 
60.14 


--- Page 23 ---
B_BVP 
VLF 
6 
543.83 
621.41 
566.39 
1499.95 
 
 
Table 20: Change from pre-patch to last-patch  (day 7) of HF, LF/HF NN50, PNN50, 
Power, RMSSD, and VLF , stratified by Epoch (1-6) 
Source 
Outcome Epoch 
Mean 
Change 
SD 
p-value 
A_EKG HF 
1 
3154.59 
29005.20 
0.68000 
A_EKG HF 
2 
-4184.73 
12598.21 
0.21910 
A_EKG HF 
3 
6019.14 
41214.98 
0.58060 
A_EKG HF 
4 
3415.29 
23353.35 
0.58010 
A_EKG HF 
5 
-5091.11 
28409.00 
0.49900 
A_EKG HF 
6 -10669.64 
31051.54 
0.22100 
A_EKG LF 
1 
43702.64 
188421.31 
0.38420 
A_EKG LF 
2 
3165.08 
51770.52 
0.81630 
A_EKG LF 
3 
9239.37 
35358.13 
0.32870 
A_EKG LF 
4 
28091.37 
104765.04 
0.31660 
A_EKG LF 
5 
3998.41 
22850.85 
0.50900 
A_EKG LF 
6 
-2024.20 
133453.31 
0.95560 
A_EKG LF/HF 
1 
0.50 
1.81 
0.30510 
A_EKG LF/HF 
2 
0.22 
1.11 
0.45440 
A_EKG LF/HF 
3 
0.09 
0.47 
0.44920 
A_EKG LF/HF 
4 
0.55 
1.70 
0.23440 
A_EKG LF/HF 
5 
0.15 
0.36 
0.11820 
A_EKG LF/HF 
6 
0.14 
1.80 
0.77260 
A_EKG NN50 
1 
-1.87 
4.50 
0.13060 
A_EKG NN50 
2 
2.40 
5.78 
0.13010 
A_EKG NN50 
3 
-0.13 
8.13 
0.95030 
A_EKG NN50 
4 
1.87 
6.82 
0.30730 
A_EKG NN50 
5 
2.00 
5.96 
0.21500 
A_EKG NN50 
6 
1.14 
6.09 
0.49480 
A_EKG PNN50 
1 
-0.01 
0.04 
0.22480 
A_EKG PNN50 
2 
0.01 
0.03 
0.44660 
A_EKG PNN50 
3 
0.00 
0.03 
0.95160 
A_EKG PNN50 
4 
0.00 
0.05 
0.71980 
A_EKG PNN50 
5 
-0.01 
0.05 
0.51460 
A_EKG PNN50 
6 
-0.01 
0.04 
0.34490 
A_EKG Power 
1 
51633.02 
253690.12 
0.44370 
A_EKG Power 
2 
-1680.88 
72944.30 
0.93020 
A_EKG Power 
3 
20500.80 
95031.26 
0.41750 
A_EKG Power 
4 
62442.52 
221196.63 
0.29270 


--- Page 24 ---
A_EKG Power 
5 
-2636.59 
48451.54 
0.83610 
A_EKG Power 
6 
4442.72 
267301.28 
0.95140 
A_EKG RMSSD 
1 
24.02 
241.70 
0.70620 
A_EKG RMSSD 
2 
-47.39 
118.28 
0.14300 
A_EKG RMSSD 
3 
17.51 
294.04 
0.82090 
A_EKG RMSSD 
4 
1.79 
198.97 
0.97270 
A_EKG RMSSD 
5 
-63.85 
214.48 
0.26820 
A_EKG RMSSD 
6 
-42.95 
211.64 
0.46120 
A_EKG SDNN 
1 
28.08 
208.21 
0.60960 
A_EKG SDNN 
2 
-42.89 
82.71 
0.06430 
A_EKG SDNN 
3 
20.75 
209.31 
0.70680 
A_EKG SDNN 
4 
5.58 
147.42 
0.88550 
A_EKG SDNN 
5 
-32.43 
145.93 
0.40390 
A_EKG SDNN 
6 
-43.01 
148.53 
0.29830 
A_EKG VLF 
1 
4775.80 
41081.08 
0.65940 
A_EKG VLF 
2 
-661.23 
17028.51 
0.88260 
A_EKG VLF 
3 
5242.29 
21025.80 
0.35060 
A_EKG VLF 
4 
30935.86 
109560.83 
0.29260 
A_EKG VLF 
5 
-1543.89 
3669.04 
0.12540 
A_EKG VLF 
6 
17136.56 
120381.27 
0.60330 
B_BVP 
HF 
1 
-119.00 
1129.86 
0.68950 
B_BVP 
HF 
2 
-2745.42 
7692.69 
0.18860 
B_BVP 
HF 
3 
-396.41 
1771.01 
0.40060 
B_BVP 
HF 
4 
540.54 
2849.49 
0.47470 
B_BVP 
HF 
5 
-1085.13 
2038.55 
0.05830 
B_BVP 
HF 
6 
-969.55 
3551.06 
0.32560 
B_BVP 
LF 
1 
561.24 
2192.12 
0.33820 
B_BVP 
LF 
2 
-933.75 
8693.08 
0.68370 
B_BVP 
LF 
3 
239.78 
1035.47 
0.38500 
B_BVP 
LF 
4 
-95.13 
948.78 
0.70360 
B_BVP 
LF 
5 
457.61 
4474.31 
0.69800 
B_BVP 
LF 
6 
1071.09 
4533.33 
0.39270 
B_BVP 
LF/HF 
1 
0.82 
4.23 
0.46800 
B_BVP 
LF/HF 
2 
-0.29 
8.11 
0.89130 
B_BVP 
LF/HF 
3 
0.71 
6.18 
0.66280 
B_BVP 
LF/HF 
4 
-1.06 
8.15 
0.62380 
B_BVP 
LF/HF 
5 
-0.58 
3.98 
0.57940 
B_BVP 
LF/HF 
6 
-0.27 
4.10 
0.80980 
B_BVP 
NN50 
1 
-3.13 
5.34 
0.03950 
B_BVP 
NN50 
2 
-2.13 
4.12 
0.06470 
B_BVP 
NN50 
3 
-1.73 
2.89 
0.03580 


--- Page 25 ---
B_BVP 
NN50 
4 
-0.67 
3.60 
0.48490 
B_BVP 
NN50 
5 
-2.73 
3.03 
0.00360 
B_BVP 
NN50 
6 
-1.14 
3.37 
0.22680 
B_BVP 
PNN50 
1 
-0.05 
0.08 
0.03820 
B_BVP 
PNN50 
2 
-0.03 
0.07 
0.06880 
B_BVP 
PNN50 
3 
-0.03 
0.04 
0.04290 
B_BVP 
PNN50 
4 
-0.01 
0.06 
0.43010 
B_BVP 
PNN50 
5 
-0.04 
0.04 
0.00360 
B_BVP 
PNN50 
6 
-0.02 
0.05 
0.17910 
B_BVP 
Power 
1 
545.78 
2280.01 
0.36960 
B_BVP 
Power 
2 
-8328.21 
31202.70 
0.31880 
B_BVP 
Power 
3 
-214.30 
1871.40 
0.66420 
B_BVP 
Power 
4 
307.79 
3957.22 
0.76770 
B_BVP 
Power 
5 
-1009.99 
3912.89 
0.33440 
B_BVP 
Power 
6 
159.57 
8096.33 
0.94230 
B_BVP 
RMSSD 
1 
-17.35 
78.45 
0.40610 
B_BVP 
RMSSD 
2 
-45.31 
139.63 
0.22940 
B_BVP 
RMSSD 
3 
-20.12 
53.66 
0.16840 
B_BVP 
RMSSD 
4 
-3.70 
40.78 
0.73050 
B_BVP 
RMSSD 
5 
-21.13 
36.49 
0.04160 
B_BVP 
RMSSD 
6 
-16.81 
66.48 
0.36130 
B_BVP 
SDNN 
1 
-14.88 
51.26 
0.27970 
B_BVP 
SDNN 
2 
-36.68 
127.28 
0.28320 
B_BVP 
SDNN 
3 
-14.89 
36.20 
0.13350 
B_BVP 
SDNN 
4 
-5.96 
38.00 
0.55320 
B_BVP 
SDNN 
5 
-19.42 
27.08 
0.01480 
B_BVP 
SDNN 
6 
-15.82 
50.23 
0.25970 
B_BVP 
VLF 
1 
103.55 
547.35 
0.47580 
B_BVP 
VLF 
2 
-4649.04 
16958.99 
0.30630 
B_BVP 
VLF 
3 
-57.67 
573.83 
0.70290 
B_BVP 
VLF 
4 
-137.63 
741.02 
0.48380 
B_BVP 
VLF 
5 
-382.47 
426.65 
0.00370 
B_BVP 
VLF 
6 
58.02 
1755.00 
0.90340 
 
 
 
 
 
Table 21: Summary statistics for pre- vs. Last patch (day 7) of HF, LF/HF NN50, PNN50, 
Power, RMSSD, and VLF , across all 6 Epochs 
 
 
Pre-patch 
Last-patch (Day 7) 


--- Page 26 ---
Source 
Outcome Mean 
SD 
Mean 
SD 
A_EKG HF 
23893.77 
18487.28 
22778.77 
24740.27 
A_EKG LF 
17020.81 
39992.04 
31445.25 
96188.86 
A_EKG LF/HF 
0.65 
0.74 
0.92 
1.08 
A_EKG NN50 
38.32 
5.43 
39.16 
5.93 
A_EKG PNN50 
0.44 
0.03 
0.44 
0.03 
A_EKG Power 
47640.73 
67916.09 
70076.42 
166485.72 
A_EKG RMSSD 
546.19 
166.44 
527.98 
201.30 
A_EKG SDNN 
372.10 
112.67 
361.59 
148.66 
A_EKG VLF 
6726.15 
19705.90 
15852.41 
63648.29 
B_BVP 
HF 
2006.26 
5250.16 
1219.54 
3722.92 
B_BVP 
LF 
1212.62 
3001.00 
1418.10 
4216.50 
B_BVP 
LF/HF 
3.71 
5.33 
3.64 
3.27 
B_BVP 
NN50 
4.86 
5.79 
2.90 
4.04 
B_BVP 
PNN50 
0.07 
0.09 
0.04 
0.05 
B_BVP 
Power 
4346.12 
13669.71 
2919.37 
7809.44 
B_BVP 
RMSSD 
75.74 
94.85 
53.97 
81.91 
B_BVP 
SDNN 
70.89 
71.80 
52.28 
63.04 
B_BVP 
VLF 
1127.24 
6929.44 
281.73 
698.56 
 
 
 
Table 22: Change from pre-patch to last-patch  (day 7) of HF, LF/HF NN50, PNN50, 
Power, RMSSD, and VLF , across all 6 Epochs 
Source 
Outcome 
Mean 
Change 
SD 
p-
value 
A_EKG HF 
-1115.01 
28492.47 
0.7113 
A_EKG LF 
14424.43 
104293.22 
0.1929 
A_EKG LF/HF 
0.28 
1.31 
0.0487 
A_EKG NN50 
0.83 
6.31 
0.2133 
A_EKG PNN50 
0.00 
0.04 
0.3994 
A_EKG Power 
22435.68 
177642.61 
0.2340 
A_EKG RMSSD 
-18.22 
214.87 
0.4234 
A_EKG SDNN 
-10.50 
160.20 
0.5356 
A_EKG VLF 
9126.26 
67230.39 
0.2012 
B_BVP 
HF 
-786.72 
3852.92 
0.0559 
B_BVP 
LF 
205.48 
4414.61 
0.6599 
B_BVP 
LF/HF 
-0.08 
5.93 
0.9004 
B_BVP 
NN50 
-1.96 
3.80 <.0001 
B_BVP 
PNN50 
-0.03 
0.06 <.0001 
B_BVP 
Power 
-1426.75 
13373.42 
0.3142 


--- Page 27 ---
B_BVP 
RMSSD 
-21.78 
76.48 
0.0083 
B_BVP 
SDNN 
-18.60 
63.27 
0.0065 
B_BVP 
VLF 
-845.51 
6989.71 
0.2542 
 
 
Table 23: Summary statistics for pre- vs. Last patch (day 7) of BVP-HR, EMG, Skin-
Condition, Temperature and Respiratory Rate  for all distribution characteristics 
outcomes, stratified by Epoch (1-6) 
 
 
 
Pre-patch 
Last-patch (day 7) 
Source 
Outcome 
Epoch 
Mean 
SD 
Mean 
SD 
BVP_HR 
1:Average 
1 
75.99 
12.00 
79.45 
13.01 
BVP_HR 
1:Average 
2 
75.38 
10.23 
79.89 
12.91 
BVP_HR 
1:Average 
3 
77.08 
12.44 
80.32 
12.58 
BVP_HR 
1:Average 
4 
78.22 
12.40 
79.91 
14.13 
BVP_HR 
1:Average 
5 
79.37 
12.55 
79.85 
13.40 
BVP_HR 
1:Average 
6 
78.22 
12.22 
79.95 
13.35 
BVP_HR 
2:Mode 
1 
76.27 
14.47 
78.57 
12.18 
BVP_HR 
2:Mode 
2 
77.70 
12.81 
80.04 
14.03 
BVP_HR 
2:Mode 
3 
77.26 
13.21 
80.53 
13.90 
BVP_HR 
2:Mode 
4 
79.69 
13.43 
81.49 
15.08 
BVP_HR 
2:Mode 
5 
79.33 
13.43 
80.63 
12.79 
BVP_HR 
2:Mode 
6 
78.50 
13.00 
80.71 
13.42 
BVP_HR 
4:STD 
1 
5.51 
4.65 
4.50 
4.18 
BVP_HR 
4:STD 
2 
6.45 
7.38 
4.27 
3.93 
BVP_HR 
4:STD 
3 
5.10 
3.47 
4.49 
3.83 
BVP_HR 
4:STD 
4 
5.18 
3.87 
4.56 
4.12 
BVP_HR 
4:STD 
5 
5.70 
4.42 
3.71 
3.60 
BVP_HR 
4:STD 
6 
5.72 
4.61 
4.25 
3.63 
BVP_HR 
5:Minimum 
1 
59.46 
15.13 
66.60 
18.60 
BVP_HR 
5:Minimum 
2 
58.19 
14.63 
69.53 
17.78 
BVP_HR 
5:Minimum 
3 
58.87 
14.55 
68.21 
15.42 
BVP_HR 
5:Minimum 
4 
64.41 
13.91 
68.17 
17.42 
BVP_HR 
5:Minimum 
5 
62.90 
17.58 
69.68 
16.71 
BVP_HR 
5:Minimum 
6 
61.42 
16.43 
65.95 
18.28 
BVP_HR 
6:Maximum 
1 
94.49 
27.71 
89.97 
17.16 
BVP_HR 
6:Maximum 
2 
90.18 
27.03 
87.47 
12.96 
BVP_HR 
6:Maximum 
3 
86.36 
13.21 
92.06 
17.68 
BVP_HR 
6:Maximum 
4 
90.52 
17.51 
88.19 
14.42 
BVP_HR 
6:Maximum 
5 
93.50 
19.71 
86.78 
13.82 
BVP_HR 
6:Maximum 
6 
87.79 
13.16 
87.53 
14.14 


--- Page 28 ---
BVP_HR_Max_Min 1:Average 
1 
9.64 
9.75 
9.10 
10.49 
BVP_HR_Max_Min 1:Average 
2 
11.32 
12.49 
8.03 
9.49 
BVP_HR_Max_Min 1:Average 
3 
9.37 
8.36 
8.04 
8.21 
BVP_HR_Max_Min 1:Average 
4 
8.97 
8.17 
8.34 
9.25 
BVP_HR_Max_Min 1:Average 
5 
9.21 
8.51 
6.98 
6.97 
BVP_HR_Max_Min 1:Average 
6 
10.00 
10.85 
8.16 
8.97 
BVP_HR_Max_Min 2:Mode 
1 
7.27 
11.25 
6.09 
11.16 
BVP_HR_Max_Min 2:Mode 
2 
7.52 
11.82 
6.79 
11.22 
BVP_HR_Max_Min 2:Mode 
3 
4.98 
3.55 
6.87 
10.80 
BVP_HR_Max_Min 2:Mode 
4 
7.08 
11.08 
7.25 
11.03 
BVP_HR_Max_Min 2:Mode 
5 
7.64 
11.65 
6.58 
10.58 
BVP_HR_Max_Min 2:Mode 
6 
7.53 
12.04 
6.49 
10.57 
BVP_HR_Max_Min 4:STD 
1 
7.26 
6.74 
5.98 
7.28 
BVP_HR_Max_Min 4:STD 
2 
7.90 
11.18 
4.26 
4.46 
BVP_HR_Max_Min 4:STD 
3 
6.65 
6.04 
5.53 
6.42 
BVP_HR_Max_Min 4:STD 
4 
6.01 
6.82 
4.43 
5.02 
BVP_HR_Max_Min 4:STD 
5 
6.96 
6.55 
4.32 
5.47 
BVP_HR_Max_Min 4:STD 
6 
6.04 
6.01 
4.81 
5.32 
BVP_HR_Max_Min 5:Minimum 
1 
2.64 
1.92 
2.08 
2.34 
BVP_HR_Max_Min 5:Minimum 
2 
2.54 
2.81 
1.87 
0.92 
BVP_HR_Max_Min 5:Minimum 
3 
2.48 
2.65 
2.05 
1.63 
BVP_HR_Max_Min 5:Minimum 
4 
3.01 
2.30 
2.36 
2.20 
BVP_HR_Max_Min 5:Minimum 
5 
2.23 
1.47 
1.87 
1.65 
BVP_HR_Max_Min 5:Minimum 
6 
2.80 
2.05 
2.08 
2.61 
BVP_HR_Max_Min 6:Maximum 
1 
26.71 
23.26 
20.79 
22.32 
BVP_HR_Max_Min 6:Maximum 
2 
26.85 
32.23 
14.99 
12.29 
BVP_HR_Max_Min 6:Maximum 
3 
23.55 
15.58 
19.43 
20.18 
BVP_HR_Max_Min 6:Maximum 
4 
21.30 
19.80 
15.63 
13.79 
BVP_HR_Max_Min 6:Maximum 
5 
24.39 
21.09 
14.86 
14.52 
BVP_HR_Max_Min 6:Maximum 
6 
22.54 
16.95 
17.73 
16.94 
C_EMG 
1:Average 
1 
73.73 
147.15 
26.37 
38.59 
C_EMG 
1:Average 
2 
62.98 
136.67 
21.32 
26.87 
C_EMG 
1:Average 
3 
53.38 
130.88 
20.44 
26.37 
C_EMG 
1:Average 
4 
54.91 
138.45 
17.39 
24.66 
C_EMG 
1:Average 
5 
54.77 
133.63 
19.50 
30.49 
C_EMG 
1:Average 
6 
56.37 
116.57 
13.53 
17.62 
C_EMG 
2:Mode 
1 
88.48 
192.35 
16.98 
26.42 
C_EMG 
2:Mode 
2 
53.96 
136.32 
22.29 
28.61 
C_EMG 
2:Mode 
3 
54.69 
138.62 
17.93 
24.91 
C_EMG 
2:Mode 
4 
52.50 
130.22 
15.97 
23.43 
C_EMG 
2:Mode 
5 
51.44 
127.80 
19.13 
31.35 


--- Page 29 ---
C_EMG 
2:Mode 
6 
34.90 
62.74 
13.34 
18.16 
C_EMG 
3:Area 
1 
4423.89 
8828.48 
1581.98 
2315.16 
C_EMG 
3:Area 
2 
3778.68 
8200.12 
1278.93 
1612.16 
C_EMG 
3:Area 
3 
3203.01 
7853.07 
1226.24 
1582.10 
C_EMG 
3:Area 
4 
3294.39 
8306.75 
1043.60 
1479.42 
C_EMG 
3:Area 
5 
3286.20 
8017.55 
1170.05 
1829.65 
C_EMG 
3:Area 
6 
3382.44 
6993.89 
811.79 
1057.38 
C_EMG 
4:STD 
1 
13.00 
20.72 
14.54 
43.83 
C_EMG 
4:STD 
2 
15.68 
41.10 
3.76 
6.59 
C_EMG 
4:STD 
3 
4.53 
6.93 
4.98 
10.52 
C_EMG 
4:STD 
4 
3.71 
6.56 
3.58 
5.68 
C_EMG 
4:STD 
5 
6.89 
9.77 
3.77 
8.27 
C_EMG 
4:STD 
6 
20.60 
47.69 
2.00 
1.79 
C_EMG 
5:Minimum 
1 
15.56 
18.27 
12.55 
21.69 
C_EMG 
5:Minimum 
2 
28.80 
73.99 
14.71 
23.93 
C_EMG 
5:Minimum 
3 
42.99 
111.72 
14.22 
22.04 
C_EMG 
5:Minimum 
4 
47.15 
122.87 
12.08 
20.81 
C_EMG 
5:Minimum 
5 
43.12 
114.12 
9.31 
17.09 
C_EMG 
5:Minimum 
6 
24.77 
44.54 
9.94 
15.24 
C_EMG 
6:Maximum 
1 
192.25 
244.06 
103.39 
172.63 
C_EMG 
6:Maximum 
2 
155.35 
237.25 
63.62 
82.52 
C_EMG 
6:Maximum 
3 
99.71 
164.04 
74.06 
155.55 
C_EMG 
6:Maximum 
4 
92.75 
161.73 
87.60 
144.18 
C_EMG 
6:Maximum 
5 
128.73 
188.45 
73.03 
155.09 
C_EMG 
6:Maximum 
6 
123.22 
212.92 
41.55 
36.64 
D_EMG 
1:Average 
1 
28.81 
55.86 
41.70 
93.73 
D_EMG 
1:Average 
2 
44.06 
99.54 
35.15 
70.91 
D_EMG 
1:Average 
3 
30.77 
68.94 
20.33 
30.85 
D_EMG 
1:Average 
4 
24.10 
56.73 
25.32 
53.58 
D_EMG 
1:Average 
5 
25.06 
64.03 
25.62 
55.95 
D_EMG 
1:Average 
6 
33.05 
92.75 
30.84 
69.95 
D_EMG 
2:Mode 
1 
19.34 
33.17 
38.98 
99.90 
D_EMG 
2:Mode 
2 
32.81 
80.55 
15.36 
22.12 
D_EMG 
2:Mode 
3 
32.48 
74.52 
20.35 
34.43 
D_EMG 
2:Mode 
4 
23.25 
57.01 
19.20 
36.53 
D_EMG 
2:Mode 
5 
24.23 
64.31 
22.08 
46.41 
D_EMG 
2:Mode 
6 
32.19 
94.53 
32.10 
76.54 
D_EMG 
3:Area 
1 
1728.66 
3351.40 
2501.91 
5623.55 
D_EMG 
3:Area 
2 
2643.37 
5972.58 
2108.70 
4254.80 
D_EMG 
3:Area 
3 
1846.15 
4136.32 
1219.72 
1850.73 
D_EMG 
3:Area 
4 
1446.25 
3403.70 
1518.91 
3214.78 


--- Page 30 ---
D_EMG 
3:Area 
5 
1503.30 
3842.00 
1537.14 
3357.02 
D_EMG 
3:Area 
6 
1983.18 
5564.93 
1850.20 
4197.23 
D_EMG 
4:STD 
1 
16.20 
29.48 
12.88 
32.89 
D_EMG 
4:STD 
2 
15.59 
26.52 
20.35 
44.28 
D_EMG 
4:STD 
3 
7.36 
14.41 
8.05 
16.97 
D_EMG 
4:STD 
4 
4.56 
6.66 
11.63 
35.16 
D_EMG 
4:STD 
5 
5.49 
8.41 
6.50 
17.55 
D_EMG 
4:STD 
6 
7.30 
11.31 
3.43 
5.83 
D_EMG 
5:Minimum 
1 
11.57 
25.03 
23.23 
57.11 
D_EMG 
5:Minimum 
2 
23.17 
65.59 
4.87 
6.08 
D_EMG 
5:Minimum 
3 
8.47 
21.57 
7.63 
12.84 
D_EMG 
5:Minimum 
4 
17.45 
47.49 
8.75 
21.38 
D_EMG 
5:Minimum 
5 
17.38 
50.10 
8.74 
21.37 
D_EMG 
5:Minimum 
6 
20.08 
60.38 
16.09 
32.52 
D_EMG 
6:Maximum 
1 
171.84 
224.33 
115.20 
187.23 
D_EMG 
6:Maximum 
2 
157.74 
240.03 
105.02 
206.16 
D_EMG 
6:Maximum 
3 
109.99 
178.37 
83.18 
141.87 
D_EMG 
6:Maximum 
4 
78.68 
80.34 
107.54 
164.96 
D_EMG 
6:Maximum 
5 
91.00 
135.09 
69.77 
109.58 
D_EMG 
6:Maximum 
6 
122.45 
188.78 
58.92 
95.51 
EKG_HR 
1:Average 
2 
119.69 
12.76 
120.06 
11.49 
EKG_HR 
1:Average 
3 
114.91 
8.81 
115.04 
13.02 
EKG_HR 
1:Average 
4 
109.02 
7.64 
110.87 
10.38 
EKG_HR 
1:Average 
5 
106.36 
9.83 
111.51 
7.89 
EKG_HR 
1:Average 
6 
101.74 
10.59 
105.43 
8.69 
EKG_HR 
2:Mode 
2 
80.68 
27.74 
79.53 
29.02 
EKG_HR 
2:Mode 
3 
64.20 
20.10 
63.70 
27.99 
EKG_HR 
2:Mode 
4 
51.06 
11.28 
60.64 
22.16 
EKG_HR 
2:Mode 
5 
52.27 
17.00 
55.37 
14.84 
EKG_HR 
2:Mode 
6 
47.46 
21.83 
54.49 
22.47 
EKG_HR 
4:STD 
2 
56.89 
4.98 
55.93 
7.50 
EKG_HR 
4:STD 
3 
61.09 
7.70 
58.93 
8.71 
EKG_HR 
4:STD 
4 
61.57 
8.85 
57.66 
6.93 
EKG_HR 
4:STD 
5 
62.12 
4.81 
62.13 
5.65 
EKG_HR 
4:STD 
6 
61.74 
9.36 
63.22 
6.44 
EKG_HR 
5:Minimum 
2 
35.08 
10.57 
38.26 
11.55 
EKG_HR 
5:Minimum 
3 
38.33 
7.02 
36.63 
10.92 
EKG_HR 
5:Minimum 
4 
36.34 
5.77 
36.06 
13.51 
EKG_HR 
5:Minimum 
5 
34.99 
6.41 
38.06 
9.84 
EKG_HR 
5:Minimum 
6 
30.61 
9.41 
31.98 
8.99 
EKG_HR 
6:Maximum 
2 
289.75 
12.26 
287.79 
11.22 


--- Page 31 ---
EKG_HR 
6:Maximum 
3 
292.72 
9.34 
289.50 
11.15 
EKG_HR 
6:Maximum 
4 
288.53 
13.01 
286.77 
16.66 
EKG_HR 
6:Maximum 
5 
286.46 
17.62 
288.23 
10.54 
EKG_HR 
6:Maximum 
6 
278.81 
19.88 
294.45 
4.15 
EKG_HR_Max_Min 1:Average 
2 
149.43 
21.62 
145.76 
22.80 
EKG_HR_Max_Min 1:Average 
3 
155.05 
13.59 
149.86 
13.95 
EKG_HR_Max_Min 1:Average 
4 
152.38 
24.86 
143.01 
23.95 
EKG_HR_Max_Min 1:Average 
5 
154.93 
21.73 
153.72 
19.80 
EKG_HR_Max_Min 1:Average 
6 
143.16 
28.85 
147.05 
15.49 
EKG_HR_Max_Min 2:Mode 
2 
77.04 
53.27 
94.10 
64.44 
EKG_HR_Max_Min 2:Mode 
3 
95.38 
68.18 
65.49 
53.18 
EKG_HR_Max_Min 2:Mode 
4 
64.18 
29.38 
70.20 
64.86 
EKG_HR_Max_Min 2:Mode 
5 
89.36 
66.60 
86.20 
44.44 
EKG_HR_Max_Min 2:Mode 
6 
81.64 
67.36 
50.42 
32.38 
EKG_HR_Max_Min 4:STD 
2 
59.35 
8.66 
56.69 
13.89 
EKG_HR_Max_Min 4:STD 
3 
62.24 
9.62 
61.67 
14.11 
EKG_HR_Max_Min 4:STD 
4 
61.38 
8.95 
60.50 
10.86 
EKG_HR_Max_Min 4:STD 
5 
60.83 
11.90 
61.78 
14.01 
EKG_HR_Max_Min 4:STD 
6 
62.13 
12.79 
69.43 
8.42 
EKG_HR_Max_Min 5:Minimum 
2 
55.38 
32.74 
58.32 
37.28 
EKG_HR_Max_Min 5:Minimum 
3 
52.16 
18.12 
47.72 
25.92 
EKG_HR_Max_Min 5:Minimum 
4 
53.76 
27.95 
48.74 
34.97 
EKG_HR_Max_Min 5:Minimum 
5 
59.60 
33.62 
63.48 
35.49 
EKG_HR_Max_Min 5:Minimum 
6 
58.48 
41.86 
44.07 
26.02 
EKG_HR_Max_Min 6:Maximum 
2 
239.95 
17.21 
232.74 
23.85 
EKG_HR_Max_Min 6:Maximum 
3 
243.42 
15.10 
240.36 
21.29 
EKG_HR_Max_Min 6:Maximum 
4 
241.38 
18.73 
240.92 
25.28 
EKG_HR_Max_Min 6:Maximum 
5 
242.32 
18.77 
242.68 
17.09 
EKG_HR_Max_Min 6:Maximum 
6 
242.12 
21.17 
251.81 
10.15 
E_Skin_Cond 
1:Average 
1 
1.03 
0.92 
1.12 
0.83 
E_Skin_Cond 
1:Average 
2 
1.06 
0.96 
1.15 
0.92 
E_Skin_Cond 
1:Average 
3 
1.16 
1.08 
1.18 
0.95 
E_Skin_Cond 
1:Average 
4 
1.25 
1.19 
1.21 
1.02 
E_Skin_Cond 
1:Average 
5 
1.32 
1.45 
1.28 
1.13 
E_Skin_Cond 
1:Average 
6 
1.39 
1.41 
1.31 
1.22 
E_Skin_Cond 
2:Mode 
1 
0.96 
0.71 
1.09 
0.81 
E_Skin_Cond 
2:Mode 
2 
1.02 
0.83 
1.15 
0.93 
E_Skin_Cond 
2:Mode 
3 
1.11 
1.00 
1.17 
0.93 
E_Skin_Cond 
2:Mode 
4 
1.23 
1.16 
1.19 
0.99 
E_Skin_Cond 
2:Mode 
5 
1.24 
1.22 
1.27 
1.11 
E_Skin_Cond 
2:Mode 
6 
1.38 
1.39 
1.30 
1.20 


--- Page 32 ---
E_Skin_Cond 
3:Area 
1 
61.83 
55.14 
67.10 
49.90 
E_Skin_Cond 
3:Area 
2 
63.86 
57.53 
69.22 
55.39 
E_Skin_Cond 
3:Area 
3 
69.53 
64.95 
71.02 
57.26 
E_Skin_Cond 
3:Area 
4 
74.99 
71.21 
72.60 
61.01 
E_Skin_Cond 
3:Area 
5 
79.32 
87.27 
76.62 
67.99 
E_Skin_Cond 
3:Area 
6 
83.64 
84.39 
78.81 
73.39 
E_Skin_Cond 
4:STD 
1 
0.09 
0.21 
0.06 
0.06 
E_Skin_Cond 
4:STD 
2 
0.06 
0.10 
0.05 
0.05 
E_Skin_Cond 
4:STD 
3 
0.08 
0.09 
0.05 
0.07 
E_Skin_Cond 
4:STD 
4 
0.06 
0.07 
0.05 
0.07 
E_Skin_Cond 
4:STD 
5 
0.10 
0.23 
0.05 
0.08 
E_Skin_Cond 
4:STD 
6 
0.05 
0.06 
0.05 
0.06 
E_Skin_Cond 
5:Minimum 
1 
0.90 
0.65 
1.02 
0.75 
E_Skin_Cond 
5:Minimum 
2 
0.97 
0.82 
1.07 
0.85 
E_Skin_Cond 
5:Minimum 
3 
1.05 
0.97 
1.09 
0.86 
E_Skin_Cond 
5:Minimum 
4 
1.16 
1.08 
1.12 
0.94 
E_Skin_Cond 
5:Minimum 
5 
1.18 
1.16 
1.19 
1.02 
E_Skin_Cond 
5:Minimum 
6 
1.31 
1.33 
1.24 
1.12 
E_Skin_Cond 
6:Maximum 
1 
1.23 
1.36 
1.28 
0.98 
E_Skin_Cond 
6:Maximum 
2 
1.22 
1.25 
1.27 
1.03 
E_Skin_Cond 
6:Maximum 
3 
1.35 
1.36 
1.32 
1.12 
E_Skin_Cond 
6:Maximum 
4 
1.40 
1.39 
1.34 
1.16 
E_Skin_Cond 
6:Maximum 
5 
1.54 
1.92 
1.41 
1.34 
E_Skin_Cond 
6:Maximum 
6 
1.54 
1.59 
1.44 
1.39 
F_Temp 
1:Average 
1 
33.71 
1.49 
33.45 
1.55 
F_Temp 
1:Average 
2 
33.71 
1.47 
33.54 
1.60 
F_Temp 
1:Average 
3 
33.78 
1.54 
33.58 
1.66 
F_Temp 
1:Average 
4 
33.80 
1.56 
33.65 
1.66 
F_Temp 
1:Average 
5 
33.78 
1.56 
33.72 
1.62 
F_Temp 
1:Average 
6 
33.60 
1.56 
33.75 
1.66 
F_Temp 
2:Mode 
1 
33.67 
1.49 
33.48 
1.55 
F_Temp 
2:Mode 
2 
33.71 
1.48 
33.53 
1.61 
F_Temp 
2:Mode 
3 
33.78 
1.55 
33.59 
1.67 
F_Temp 
2:Mode 
4 
33.81 
1.56 
33.64 
1.70 
F_Temp 
2:Mode 
5 
33.78 
1.57 
33.73 
1.62 
F_Temp 
2:Mode 
6 
33.61 
1.56 
33.72 
1.64 
F_Temp 
3:Area 
1 
2022.30 
89.43 
2007.15 
93.01 
F_Temp 
3:Area 
2 
2022.78 
87.93 
2012.27 
96.14 
F_Temp 
3:Area 
3 
2027.00 
92.48 
2014.61 
99.75 
F_Temp 
3:Area 
4 
2028.09 
93.68 
2019.13 
99.63 
F_Temp 
3:Area 
5 
2026.95 
93.80 
2023.50 
96.96 


--- Page 33 ---
F_Temp 
3:Area 
6 
2015.76 
93.77 
2025.01 
99.85 
F_Temp 
4:STD 
1 
0.10 
0.09 
0.10 
0.06 
F_Temp 
4:STD 
2 
0.08 
0.05 
0.07 
0.03 
F_Temp 
4:STD 
3 
0.09 
0.06 
0.07 
0.03 
F_Temp 
4:STD 
4 
0.08 
0.04 
0.09 
0.06 
F_Temp 
4:STD 
5 
0.08 
0.05 
0.08 
0.06 
F_Temp 
4:STD 
6 
0.08 
0.04 
0.09 
0.05 
F_Temp 
5:Minimum 
1 
33.52 
1.47 
33.28 
1.58 
F_Temp 
5:Minimum 
2 
33.58 
1.46 
33.41 
1.64 
F_Temp 
5:Minimum 
3 
33.63 
1.56 
33.45 
1.67 
F_Temp 
5:Minimum 
4 
33.65 
1.58 
33.50 
1.68 
F_Temp 
5:Minimum 
5 
33.65 
1.55 
33.58 
1.66 
F_Temp 
5:Minimum 
6 
33.45 
1.56 
33.59 
1.68 
F_Temp 
6:Maximum 
1 
33.88 
1.47 
33.62 
1.53 
F_Temp 
6:Maximum 
2 
33.86 
1.47 
33.67 
1.56 
F_Temp 
6:Maximum 
3 
33.94 
1.51 
33.71 
1.64 
F_Temp 
6:Maximum 
4 
33.94 
1.56 
33.82 
1.59 
F_Temp 
6:Maximum 
5 
33.93 
1.56 
33.88 
1.53 
F_Temp 
6:Maximum 
6 
33.73 
1.57 
33.89 
1.65 
Resp_Rate 
1:Average 
1 
13.82 
2.26 
14.27 
1.88 
Resp_Rate 
1:Average 
2 
13.79 
2.40 
14.06 
1.80 
Resp_Rate 
1:Average 
3 
13.60 
2.27 
13.72 
1.69 
Resp_Rate 
1:Average 
4 
13.65 
3.05 
13.45 
2.05 
Resp_Rate 
1:Average 
5 
13.43 
2.61 
13.59 
2.31 
Resp_Rate 
1:Average 
6 
13.72 
2.72 
13.65 
1.88 
Resp_Rate 
2:Mode 
1 
12.27 
4.17 
14.18 
4.87 
Resp_Rate 
2:Mode 
2 
13.10 
5.09 
13.55 
4.59 
Resp_Rate 
2:Mode 
3 
13.32 
4.29 
13.41 
4.65 
Resp_Rate 
2:Mode 
4 
12.92 
5.45 
13.20 
4.18 
Resp_Rate 
2:Mode 
5 
14.03 
4.37 
13.01 
4.38 
Resp_Rate 
2:Mode 
6 
14.85 
4.47 
14.68 
3.95 
Resp_Rate 
4:STD 
1 
3.29 
0.73 
3.60 
0.94 
Resp_Rate 
4:STD 
2 
3.48 
0.81 
3.47 
0.74 
Resp_Rate 
4:STD 
3 
3.75 
0.95 
3.53 
0.58 
Resp_Rate 
4:STD 
4 
3.27 
1.19 
3.48 
0.62 
Resp_Rate 
4:STD 
5 
3.39 
1.20 
3.08 
0.92 
Resp_Rate 
4:STD 
6 
3.41 
1.11 
3.32 
0.85 
Resp_Rate 
5:Minimum 
1 
8.98 
1.63 
8.69 
2.15 
Resp_Rate 
5:Minimum 
2 
8.40 
1.95 
8.47 
1.57 
Resp_Rate 
5:Minimum 
3 
7.58 
2.58 
8.39 
1.54 
Resp_Rate 
5:Minimum 
4 
8.34 
3.16 
7.57 
1.70 


--- Page 34 ---
Resp_Rate 
5:Minimum 
5 
7.85 
1.74 
8.18 
2.40 
Resp_Rate 
5:Minimum 
6 
8.31 
2.87 
8.35 
2.16 
Resp_Rate 
6:Maximum 
1 
19.06 
1.35 
19.35 
1.25 
Resp_Rate 
6:Maximum 
2 
19.04 
2.24 
19.11 
1.66 
Resp_Rate 
6:Maximum 
3 
18.88 
1.77 
19.48 
1.24 
Resp_Rate 
6:Maximum 
4 
18.37 
2.50 
19.38 
1.15 
Resp_Rate 
6:Maximum 
5 
18.03 
3.02 
18.30 
2.08 
Resp_Rate 
6:Maximum 
6 
18.92 
2.45 
18.69 
1.59 
 
 
Table 24: Change from pre-patch to last patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate for Average,Mode,and Area, stratified by Epoch (1-6) 
Source 
Outcome 
Epoch 
Mean 
Change 
SD 
p-
value 
BVP_HR 
1:Average 
1 
3.47 
8.57 
0.1393 
BVP_HR 
1:Average 
2 
4.51 
7.83 
0.0426 
BVP_HR 
1:Average 
3 
3.23 
7.87 
0.1338 
BVP_HR 
1:Average 
4 
1.69 
9.18 
0.4866 
BVP_HR 
1:Average 
5 
0.48 
8.92 
0.8378 
BVP_HR 
1:Average 
6 
2.69 
7.87 
0.2231 
BVP_HR 
2:Mode 
1 
2.29 
9.69 
0.3754 
BVP_HR 
2:Mode 
2 
2.35 
10.46 
0.3998 
BVP_HR 
2:Mode 
3 
3.26 
9.99 
0.2261 
BVP_HR 
2:Mode 
4 
1.80 
11.77 
0.5641 
BVP_HR 
2:Mode 
5 
1.30 
9.01 
0.5847 
BVP_HR 
2:Mode 
6 
3.34 
7.79 
0.1329 
BVP_HR_Max_Min 1:Average 
1 
-0.54 
4.61 
0.6583 
BVP_HR_Max_Min 1:Average 
2 
-3.29 
10.09 
0.2272 
BVP_HR_Max_Min 1:Average 
3 
-1.33 
2.98 
0.1047 
BVP_HR_Max_Min 1:Average 
4 
-0.63 
4.94 
0.6286 
BVP_HR_Max_Min 1:Average 
5 
-2.23 
3.13 
0.0153 
BVP_HR_Max_Min 1:Average 
6 
-1.73 
4.52 
0.1763 
BVP_HR_Max_Min 2:Mode 
1 
-1.18 
2.17 
0.0533 
BVP_HR_Max_Min 2:Mode 
2 
-0.73 
1.57 
0.0917 
BVP_HR_Max_Min 2:Mode 
3 
1.89 
10.29 
0.4894 
BVP_HR_Max_Min 2:Mode 
4 
0.17 
2.56 
0.8021 
BVP_HR_Max_Min 2:Mode 
5 
-1.06 
2.63 
0.1390 
BVP_HR_Max_Min 2:Mode 
6 
-0.77 
2.13 
0.2016 
C_EMG 
1:Average 
1 
-47.37 
156.16 
0.2597 
C_EMG 
1:Average 
2 
-41.66 
134.35 
0.2497 
C_EMG 
1:Average 
3 
-32.95 
120.86 
0.3090 


--- Page 35 ---
C_EMG 
1:Average 
4 
-37.51 
128.11 
0.2758 
C_EMG 
1:Average 
5 
-35.27 
112.16 
0.2434 
C_EMG 
1:Average 
6 
-42.30 
116.23 
0.1964 
C_EMG 
2:Mode 
1 
-71.50 
198.24 
0.1842 
C_EMG 
2:Mode 
2 
-31.67 
128.86 
0.3573 
C_EMG 
2:Mode 
3 
-36.76 
133.32 
0.3036 
C_EMG 
2:Mode 
4 
-36.54 
123.10 
0.2696 
C_EMG 
2:Mode 
5 
-32.31 
105.53 
0.2554 
C_EMG 
2:Mode 
6 
-21.01 
63.91 
0.2405 
C_EMG 
3:Area 
1 
-2841.91 
9369.34 
0.2597 
C_EMG 
3:Area 
2 
-2499.75 
8061.27 
0.2497 
C_EMG 
3:Area 
3 
-1976.78 
7251.87 
0.3090 
C_EMG 
3:Area 
4 
-2250.79 
7686.36 
0.2758 
C_EMG 
3:Area 
5 
-2116.15 
6729.75 
0.2434 
C_EMG 
3:Area 
6 
-2538.04 
6974.02 
0.1964 
D_EMG 
1:Average 
1 
12.89 
105.67 
0.6440 
D_EMG 
1:Average 
2 
-8.91 
100.16 
0.7356 
D_EMG 
1:Average 
3 
-10.44 
74.71 
0.5969 
D_EMG 
1:Average 
4 
1.21 
82.31 
0.9553 
D_EMG 
1:Average 
5 
0.56 
90.21 
0.9810 
D_EMG 
1:Average 
6 
-2.70 
121.61 
0.9351 
D_EMG 
2:Mode 
1 
19.63 
99.86 
0.4590 
D_EMG 
2:Mode 
2 
-17.45 
78.42 
0.4033 
D_EMG 
2:Mode 
3 
-12.13 
83.13 
0.5810 
D_EMG 
2:Mode 
4 
-4.05 
71.81 
0.8302 
D_EMG 
2:Mode 
5 
-2.15 
83.96 
0.9225 
D_EMG 
2:Mode 
6 
-0.54 
127.42 
0.9876 
D_EMG 
3:Area 
1 
773.25 
6340.13 
0.6440 
D_EMG 
3:Area 
2 
-534.67 
6009.89 
0.7355 
D_EMG 
3:Area 
3 
-626.43 
4482.69 
0.5969 
D_EMG 
3:Area 
4 
72.67 
4938.74 
0.9554 
D_EMG 
3:Area 
5 
33.84 
5412.35 
0.9810 
D_EMG 
3:Area 
6 
-161.92 
7296.73 
0.9351 
EKG_HR 
1:Average 
2 
0.37 
13.68 
0.8827 
EKG_HR 
1:Average 
3 
0.13 
14.53 
0.9736 
EKG_HR 
1:Average 
4 
1.85 
13.49 
0.6037 
EKG_HR 
1:Average 
5 
5.15 
11.79 
0.1130 
EKG_HR 
1:Average 
6 
3.93 
15.74 
0.3666 
EKG_HR 
2:Mode 
2 
-1.15 
34.63 
0.8569 
EKG_HR 
2:Mode 
3 
-0.49 
30.98 
0.9519 
EKG_HR 
2:Mode 
4 
9.58 
21.99 
0.1137 


--- Page 36 ---
EKG_HR 
2:Mode 
5 
3.09 
22.59 
0.6041 
EKG_HR 
2:Mode 
6 
6.18 
33.79 
0.5061 
EKG_HR_Max_Min 1:Average 
2 
-3.68 
29.92 
0.5063 
EKG_HR_Max_Min 1:Average 
3 
-5.19 
20.06 
0.3338 
EKG_HR_Max_Min 1:Average 
4 
-9.37 
35.70 
0.3267 
EKG_HR_Max_Min 1:Average 
5 
-1.20 
16.30 
0.7793 
EKG_HR_Max_Min 1:Average 
6 
3.92 
36.00 
0.6905 
EKG_HR_Max_Min 2:Mode 
2 
17.06 
88.11 
0.2976 
EKG_HR_Max_Min 2:Mode 
3 
-29.89 
80.06 
0.1701 
EKG_HR_Max_Min 2:Mode 
4 
6.02 
77.88 
0.7690 
EKG_HR_Max_Min 2:Mode 
5 
-3.16 
79.37 
0.8798 
EKG_HR_Max_Min 2:Mode 
6 
-33.34 
67.42 
0.0871 
E_Skin_Cond 
1:Average 
1 
0.09 
0.85 
0.6960 
E_Skin_Cond 
1:Average 
2 
0.09 
0.82 
0.6779 
E_Skin_Cond 
1:Average 
3 
0.02 
0.98 
0.9231 
E_Skin_Cond 
1:Average 
4 
-0.04 
0.92 
0.8692 
E_Skin_Cond 
1:Average 
5 
-0.05 
1.03 
0.8678 
E_Skin_Cond 
1:Average 
6 
-0.03 
0.97 
0.9008 
E_Skin_Cond 
2:Mode 
1 
0.12 
0.74 
0.5349 
E_Skin_Cond 
2:Mode 
2 
0.13 
0.77 
0.5148 
E_Skin_Cond 
2:Mode 
3 
0.07 
0.95 
0.7922 
E_Skin_Cond 
2:Mode 
4 
-0.04 
0.92 
0.8594 
E_Skin_Cond 
2:Mode 
5 
0.03 
0.89 
0.9042 
E_Skin_Cond 
2:Mode 
6 
-0.03 
0.97 
0.8988 
E_Skin_Cond 
3:Area 
1 
5.27 
51.27 
0.6963 
E_Skin_Cond 
3:Area 
2 
5.36 
49.02 
0.6785 
E_Skin_Cond 
3:Area 
3 
1.49 
58.64 
0.9231 
E_Skin_Cond 
3:Area 
4 
-2.39 
55.13 
0.8691 
E_Skin_Cond 
3:Area 
5 
-2.70 
61.68 
0.8677 
E_Skin_Cond 
3:Area 
6 
-1.97 
58.15 
0.9011 
F_Temp 
1:Average 
1 
-0.25 
1.51 
0.5273 
F_Temp 
1:Average 
2 
-0.18 
1.50 
0.6576 
F_Temp 
1:Average 
3 
-0.21 
1.48 
0.5966 
F_Temp 
1:Average 
4 
-0.15 
1.54 
0.7128 
F_Temp 
1:Average 
5 
-0.06 
1.45 
0.8797 
F_Temp 
1:Average 
6 
0.17 
1.41 
0.6557 
F_Temp 
2:Mode 
1 
-0.19 
1.46 
0.6293 
F_Temp 
2:Mode 
2 
-0.18 
1.52 
0.6535 
F_Temp 
2:Mode 
3 
-0.19 
1.46 
0.6150 
F_Temp 
2:Mode 
4 
-0.16 
1.54 
0.6851 
F_Temp 
2:Mode 
5 
-0.06 
1.52 
0.8907 


--- Page 37 ---
F_Temp 
2:Mode 
6 
0.12 
1.38 
0.7519 
F_Temp 
3:Area 
1 
-15.15 
90.55 
0.5274 
F_Temp 
3:Area 
2 
-10.51 
89.84 
0.6574 
F_Temp 
3:Area 
3 
-12.39 
88.59 
0.5966 
F_Temp 
3:Area 
4 
-8.96 
92.41 
0.7128 
F_Temp 
3:Area 
5 
-3.45 
86.90 
0.8800 
F_Temp 
3:Area 
6 
10.36 
84.89 
0.6555 
Resp_Rate 
1:Average 
1 
0.45 
1.52 
0.2686 
Resp_Rate 
1:Average 
2 
0.26 
2.15 
0.6419 
Resp_Rate 
1:Average 
3 
0.12 
2.22 
0.8423 
Resp_Rate 
1:Average 
4 
-0.20 
2.83 
0.7899 
Resp_Rate 
1:Average 
5 
0.16 
1.81 
0.7435 
Resp_Rate 
1:Average 
6 
0.10 
2.12 
0.8571 
Resp_Rate 
2:Mode 
1 
1.92 
4.03 
0.0868 
Resp_Rate 
2:Mode 
2 
0.45 
4.49 
0.7032 
Resp_Rate 
2:Mode 
3 
0.08 
4.34 
0.9409 
Resp_Rate 
2:Mode 
4 
0.28 
5.94 
0.8556 
Resp_Rate 
2:Mode 
5 
-1.02 
3.57 
0.2859 
Resp_Rate 
2:Mode 
6 
-0.06 
4.32 
0.9582 
 
 
 
Table 25: Summary statistics for pre- vs. Last patch (day 7) of BVP-HR, EMG, Skin-
Condition, Temperature and Respiratory Rate  for all distribution characteristics 
outcomes, across all 6 epochs 
 
 
Pre-patch 
Last-patch (Day 
7) 
Source 
Outcome 
Mean 
SD 
Mean 
SD 
BVP_HR 
1:Average 
77.35 
11.67 
79.90 
12.87 
BVP_HR 
2:Mode 
78.02 
13.04 
80.33 
13.24 
BVP_HR 
4:STD 
5.71 
4.85 
4.30 
3.79 
BVP_HR 
5:Minimum 
60.70 
15.14 
68.02 
16.96 
BVP_HR 
6:Maximum 
91.06 
20.82 
88.67 
14.81 
BVP_HR_Max_Min 1:Average 
9.78 
9.50 
8.11 
8.73 
BVP_HR_Max_Min 2:Mode 
6.98 
10.32 
6.68 
10.59 
BVP_HR_Max_Min 4:STD 
6.98 
7.41 
4.89 
5.61 
BVP_HR_Max_Min 5:Minimum 
2.61 
2.18 
2.05 
1.92 
BVP_HR_Max_Min 6:Maximum 
24.84 
22.28 
17.24 
16.72 
C_EMG 
1:Average 
59.20 
130.01 
19.76 
27.63 
C_EMG 
2:Mode 
56.05 
133.55 
17.61 
25.23 
C_EMG 
3:Area 
3552.07 
7800.39 
1185.43 
1657.62 


--- Page 38 ---
C_EMG 
4:STD 
10.59 
27.06 
5.44 
18.98 
C_EMG 
5:Minimum 
33.88 
87.88 
12.14 
19.88 
C_EMG 
6:Maximum 
135.41 
202.29 
73.88 
131.16 
D_EMG 
1:Average 
30.80 
72.46 
29.82 
63.93 
D_EMG 
2:Mode 
27.23 
67.56 
24.68 
58.06 
D_EMG 
3:Area 
1848.17 
4347.81 
1789.43 
3835.60 
D_EMG 
4:STD 
9.35 
18.43 
10.47 
28.32 
D_EMG 
5:Minimum 
16.30 
46.42 
11.55 
29.90 
D_EMG 
6:Maximum 
120.96 
179.72 
89.94 
152.99 
EKG_HR 
1:Average 
112.05 
12.28 
113.83 
11.66 
EKG_HR 
2:Mode 
62.81 
25.24 
65.54 
26.41 
EKG_HR 
4:STD 
60.11 
7.19 
58.97 
7.58 
EKG_HR 
5:Minimum 
35.18 
8.62 
36.54 
11.13 
EKG_HR 
6:Maximum 
287.79 
14.64 
289.09 
11.44 
EKG_HR_Max_Min 1:Average 
150.88 
22.16 
147.53 
20.04 
EKG_HR_Max_Min 2:Mode 
82.18 
58.59 
76.75 
56.55 
EKG_HR_Max_Min 4:STD 
61.09 
10.19 
61.13 
13.16 
EKG_HR_Max_Min 5:Minimum 
55.50 
31.15 
53.44 
33.24 
EKG_HR_Max_Min 6:Maximum 
241.60 
17.62 
240.21 
21.49 
E_Skin_Cond 
1:Average 
1.19 
1.15 
1.21 
1.00 
E_Skin_Cond 
2:Mode 
1.14 
1.05 
1.19 
0.98 
E_Skin_Cond 
3:Area 
71.52 
69.18 
72.56 
59.72 
E_Skin_Cond 
4:STD 
0.07 
0.14 
0.05 
0.06 
E_Skin_Cond 
5:Minimum 
1.08 
1.00 
1.12 
0.91 
E_Skin_Cond 
6:Maximum 
1.37 
1.45 
1.34 
1.15 
F_Temp 
1:Average 
33.75 
1.49 
33.62 
1.58 
F_Temp 
2:Mode 
33.75 
1.49 
33.62 
1.59 
F_Temp 
3:Area 
2024.94 
89.35 
2016.94 
95.02 
F_Temp 
4:STD 
0.08 
0.06 
0.08 
0.05 
F_Temp 
5:Minimum 
33.60 
1.49 
33.47 
1.61 
F_Temp 
6:Maximum 
33.90 
1.48 
33.77 
1.54 
Resp_Rate 
1:Average 
13.66 
2.48 
13.79 
1.91 
Resp_Rate 
2:Mode 
13.37 
4.59 
13.67 
4.36 
Resp_Rate 
4:STD 
3.43 
0.99 
3.41 
0.78 
Resp_Rate 
5:Minimum 
8.26 
2.35 
8.28 
1.93 
Resp_Rate 
6:Maximum 
18.73 
2.24 
19.05 
1.55 
 
 
 
Table 26: Change from pre-patch to last patch (day 7) of BVP-HR, EMG, Skin-Condition, 
Temperature and Respiratory Rate for Average, Mode,and Area, across all 6 Epochs 


--- Page 39 ---
Source 
Outcome 
Mean 
Change 
SD 
p-value 
BVP_HR 
1:Average 
2.54 
8.31 
0.0047 
BVP_HR 
2:Mode 
2.31 
9.60 
0.0249 
BVP_HR_Max_Min 1:Average 
-1.67 
5.50 
0.0049 
BVP_HR_Max_Min 2:Mode 
-0.31 
4.67 
0.5361 
C_EMG 
1:Average 
-39.44 
124.62 
0.0035 
C_EMG 
2:Mode 
-38.45 
128.72 
0.0057 
C_EMG 
3:Area 
-2366.63 
7477.30 
0.0035 
D_EMG 
1:Average 
-0.98 
93.72 
0.9213 
D_EMG 
2:Mode 
-2.55 
89.76 
0.7881 
D_EMG 
3:Area 
-58.74 
5623.21 
0.9213 
EKG_HR 
1:Average 
1.78 
13.68 
0.2212 
EKG_HR 
2:Mode 
2.73 
29.70 
0.3857 
EKG_HR_Max_Min 1:Average 
-3.36 
28.34 
0.2641 
EKG_HR_Max_Min 2:Mode 
-5.43 
82.06 
0.5317 
E_Skin_Cond 
1:Average 
0.02 
0.90 
0.8557 
E_Skin_Cond 
2:Mode 
0.05 
0.85 
0.5926 
E_Skin_Cond 
3:Area 
1.04 
54.01 
0.8560 
F_Temp 
1:Average 
-0.13 
1.45 
0.3849 
F_Temp 
2:Mode 
-0.13 
1.45 
0.3941 
F_Temp 
3:Area 
-8.00 
86.95 
0.3851 
Resp_Rate 
1:Average 
0.13 
2.09 
0.5621 
Resp_Rate 
2:Mode 
0.30 
4.44 
0.5281 
 
 
 
GHK- CU Study – Metabolic Data 
 
Table 1: Summary statistics for metabolic markers, stratified by assessment time point ........................ 40 
Table 2: Change from time 1 to time 2, time 2 to time 3 and time 1 to time 3 ......................................... 45 
 
Study Design: Single arm study with 3 assessment time points. 
 
Sample Size:  N=15 
 
Statistical Methods: All physio parameters were summarized in terms of means and 
standard deviation, stratified by assessment time point. Changes from day 1 (pre-patch) to 
day 2, day 2  to day 7, and day 1 to day 7 were evaluated using a paired t-test or 
nonparametric Wilcoxon Signed Rank test.  
 
 
 
 


--- Page 40 ---
Table 27: Summary statistics for metabolic markers, stratified by assessment time point 
Marker 
N 
Assessment 
Time point 
Mean 
SD 
2-amino 
15 
Day 1 (pre-
patch) 
11.82 
11.65 
2-amino 
15 
Day 2 
13.26 
10.88 
2-amino 
15 
Day 7 
14.70 
12.27 
3-MT 
15 
Day 1 (pre-
patch) 
64.46 
45.27 
3-MT 
15 
Day 2 
55.99 
39.14 
3-MT 
15 
Day 7 
52.33 
26.14 
5-HT 
15 
Day 1 (pre-
patch) 
76.14 
37.36 
5-HT 
15 
Day 2 
80.52 
43.01 
5-HT 
15 
Day 7 
82.99 
57.52 
5-HT/DA 
15 
Day 1 (pre-
patch) 
0.87 
0.90 
5-HT/DA 
15 
Day 2 
0.69 
0.62 
5-HT/DA 
15 
Day 7 
0.63 
0.44 
5-HTP 
15 
Day 1 (pre-
patch) 
49.21 
26.41 
5-HTP 
15 
Day 2 
59.70 
67.25 
5-HTP 
15 
Day 7 
46.89 
25.25 
Age 
15 
Day 1 (pre-
patch) 
61.27 
8.65 
Age 
15 
Day 2 
61.27 
8.65 
Age 
15 
Day 7 
61.27 
8.65 
Ala 
15 
Day 1 (pre-
patch) 
117.66 
45.05 
Ala 
15 
Day 2 
97.49 
42.89 
Ala 
15 
Day 7 
119.53 
74.69 
Arg 
15 
Day 1 (pre-
patch) 
5.97 
1.69 
Arg 
15 
Day 2 
5.13 
2.79 
Arg 
15 
Day 7 
7.36 
6.59 
Asn 
15 
Day 1 (pre-
patch) 
18.09 
15.41 
Asn 
15 
Day 2 
15.58 
10.84 
Asn 
15 
Day 7 
16.07 
11.14 
Asp 
15 
Day 1 (pre-
patch) 
4.99 
2.86 
Asp 
15 
Day 2 
5.29 
2.31 


--- Page 41 ---
Asp 
15 
Day 7 
4.88 
2.45 
Bala 
15 
Day 1 (pre-
patch) 
27.64 
26.24 
Bala 
15 
Day 2 
16.33 
12.97 
Bala 
15 
Day 7 
20.52 
26.90 
C-C 
15 
Day 1 (pre-
patch) 
31.37 
12.67 
C-C 
15 
Day 2 
31.57 
12.59 
C-C 
15 
Day 7 
35.51 
22.37 
Car 
15 
Day 1 (pre-
patch) 
10.67 
13.07 
Car 
15 
Day 2 
6.26 
4.94 
Car 
15 
Day 7 
6.10 
6.31 
Cit 
15 
Day 1 (pre-
patch) 
2.27 
1.25 
Cit 
15 
Day 2 
2.41 
1.40 
Cit 
15 
Day 7 
2.51 
1.25 
Cre 
15 
Day 1 (pre-
patch) 
138.07 
83.78 
Cre 
15 
Day 2 
178.40 108.96 
Cre 
15 
Day 7 
172.73 120.95 
Cys 
15 
Day 1 (pre-
patch) 
57.45 
27.87 
Cys 
15 
Day 2 
66.58 
27.24 
Cys 
15 
Day 7 
50.50 
11.58 
Cys/C-c 
15 
Day 1 (pre-
patch) 
2.29 
1.82 
Cys/C-c 
15 
Day 2 
2.64 
1.95 
Cys/C-c 
15 
Day 7 
2.21 
2.14 
Cystathion 
15 
Day 1 (pre-
patch) 
9.94 
6.25 
Cystathion 
15 
Day 2 
10.82 
7.78 
Cystathion 
15 
Day 7 
9.54 
9.63 
DA 
15 
Day 1 (pre-
patch) 
154.62 
71.19 
DA 
15 
Day 2 
151.33 
53.82 
DA 
15 
Day 7 
161.26 
58.60 
E 
15 
Day 1 (pre-
patch) 
5.44 
3.27 
E 
15 
Day 2 
3.34 
1.60 
E 
15 
Day 7 
4.93 
3.02 
GABA 
15 
Day 1 (pre-
patch) 
3.79 
1.77 


--- Page 42 ---
GABA 
15 
Day 2 
3.25 
1.19 
GABA 
15 
Day 7 
3.07 
1.13 
GSH 
15 
Day 1 (pre-
patch) 
1.35 
1.40 
GSH 
15 
Day 2 
1.58 
1.48 
GSH 
15 
Day 7 
2.09 
1.71 
Gln 
15 
Day 1 (pre-
patch) 
174.16 
97.68 
Gln 
15 
Day 2 
149.88 
77.00 
Gln 
15 
Day 7 
147.20 
52.69 
Glu 
15 
Day 1 (pre-
patch) 
18.22 
11.34 
Glu 
15 
Day 2 
16.21 
8.32 
Glu 
15 
Day 7 
12.40 
5.45 
Gly 
15 
Day 1 (pre-
patch) 
272.51 182.74 
Gly 
15 
Day 2 
199.97 122.82 
Gly 
15 
Day 7 
234.64 155.33 
HCys2 
15 
Day 1 (pre-
patch) 
0.86 
0.49 
HCys2 
15 
Day 2 
1.21 
0.52 
HCys2 
15 
Day 7 
1.13 
0.60 
HYP 
15 
Day 1 (pre-
patch) 
2.55 
1.18 
HYP 
15 
Day 2 
2.19 
0.87 
HYP 
15 
Day 7 
2.21 
0.65 
Hcys 
15 
Day 1 (pre-
patch) 
0.91 
0.49 
Hcys 
15 
Day 2 
0.97 
0.63 
Hcys 
15 
Day 7 
1.07 
0.64 
His 
15 
Day 1 (pre-
patch) 
182.17 
75.01 
His 
15 
Day 2 
135.85 
60.51 
His 
15 
Day 7 
135.53 
57.98 
Hist 
15 
Day 1 (pre-
patch) 
28.77 
24.03 
Hist 
15 
Day 2 
19.52 
12.04 
Hist 
15 
Day 7 
24.35 
29.92 
Hlys 
15 
Day 1 (pre-
patch) 
1.23 
1.97 
Hlys 
15 
Day 2 
0.61 
0.67 
Hlys 
15 
Day 7 
0.43 
0.30 
Hser 
15 
Day 1 (pre-
11.63 
8.21 


--- Page 43 ---
patch) 
Hser 
15 
Day 2 
8.53 
6.01 
Hser 
15 
Day 7 
9.12 
6.65 
Ile 
15 
Day 1 (pre-
patch) 
14.10 
7.32 
Ile 
15 
Day 2 
12.11 
4.04 
Ile 
15 
Day 7 
11.30 
4.75 
LDOPA 
15 
Day 1 (pre-
patch) 
21.31 
13.72 
LDOPA 
15 
Day 2 
23.32 
10.67 
LDOPA 
15 
Day 7 
22.80 
12.70 
Leu 
15 
Day 1 (pre-
patch) 
19.98 
8.16 
Leu 
15 
Day 2 
15.13 
4.94 
Leu 
15 
Day 7 
17.10 
7.83 
Lys 
15 
Day 1 (pre-
patch) 
49.09 
32.44 
Lys 
15 
Day 2 
40.21 
29.33 
Lys 
15 
Day 7 
41.45 
34.56 
ME 
15 
Day 1 (pre-
patch) 
23.52 
16.61 
ME 
15 
Day 2 
19.24 
8.73 
ME 
15 
Day 7 
17.79 
7.79 
Met 
15 
Day 1 (pre-
patch) 
7.08 
5.74 
Met 
15 
Day 2 
6.65 
3.93 
Met 
15 
Day 7 
6.36 
3.88 
NE 
15 
Day 1 (pre-
patch) 
26.29 
13.51 
NE 
15 
Day 2 
25.52 
15.95 
NE 
15 
Day 7 
36.02 
38.37 
NE/E 
15 
Day 1 (pre-
patch) 
7.44 
6.59 
NE/E 
15 
Day 2 
10.35 
9.99 
NE/E 
15 
Day 7 
12.07 
13.78 
NorM 
15 
Day 1 (pre-
patch) 
89.67 
52.78 
NorM 
15 
Day 2 
89.67 
41.19 
NorM 
15 
Day 7 
76.61 
27.62 
Orn 
15 
Day 1 (pre-
patch) 
13.57 
10.95 
Orn 
15 
Day 2 
10.27 
7.72 
Orn 
15 
Day 7 
11.77 
11.33 


--- Page 44 ---
PEA 
15 
Day 1 (pre-
patch) 
2.08 
1.92 
PEA 
15 
Day 2 
1.91 
2.04 
PEA 
15 
Day 7 
1.48 
1.25 
Phe 
15 
Day 1 (pre-
patch) 
22.92 
14.05 
Phe 
15 
Day 2 
18.79 
9.87 
Phe 
15 
Day 7 
25.11 
12.30 
Pro 
15 
Day 1 (pre-
patch) 
13.00 
6.54 
Pro 
15 
Day 2 
10.65 
4.54 
Pro 
15 
Day 7 
10.70 
6.17 
Ratio 
15 
Day 1 (pre-
patch) 
1.60 
1.50 
Ratio 
15 
Day 2 
0.89 
0.47 
Ratio 
15 
Day 7 
1.35 
1.36 
Sar 
15 
Day 1 (pre-
patch) 
10.05 
5.57 
Sar 
15 
Day 2 
9.83 
7.58 
Sar 
15 
Day 7 
10.04 
7.57 
Ser 
15 
Day 1 (pre-
patch) 
77.68 
42.05 
Ser 
15 
Day 2 
74.23 
45.67 
Ser 
15 
Day 7 
68.77 
31.37 
Thr 
15 
Day 1 (pre-
patch) 
68.86 
41.99 
Thr 
15 
Day 2 
62.84 
38.12 
Thr 
15 
Day 7 
63.39 
40.77 
Trp 
15 
Day 1 (pre-
patch) 
21.08 
11.49 
Trp 
15 
Day 2 
27.49 
20.64 
Trp 
15 
Day 7 
16.69 
12.78 
Tryp 
15 
Day 1 (pre-
patch) 
0.68 
0.18 
Tryp 
15 
Day 2 
0.66 
0.21 
Tryp 
15 
Day 7 
0.72 
0.24 
Tyr 
15 
Day 1 (pre-
patch) 
36.35 
21.55 
Tyr 
15 
Day 2 
39.53 
21.00 
Tyr 
15 
Day 7 
38.79 
21.25 
Tyra 
15 
Day 1 (pre-
patch) 
5.64 
2.76 
Tyra 
15 
Day 2 
4.60 
1.86 


--- Page 45 ---
Tyra 
15 
Day 7 
4.97 
2.31 
Val 
15 
Day 1 (pre-
patch) 
45.11 
41.02 
Val 
15 
Day 2 
34.25 
24.67 
Val 
15 
Day 7 
41.84 
28.03 
a-amino 
15 
Day 1 (pre-
patch) 
18.79 
16.63 
a-amino 
15 
Day 2 
15.18 
9.86 
a-amino 
15 
Day 7 
9.90 
5.57 
b-aminoiso 
15 
Day 1 (pre-
patch) 
80.13 
76.39 
b-aminoiso 
15 
Day 2 
98.49 178.48 
b-aminoiso 
15 
Day 7 
59.81 
51.33 
 
 
 
Table 28: Change from day 1 (pre-patch) to day 2, day 2 to day 7, and day 1 (pre-patch) to day 7 
Marker 
Change 
Mean 
Change 
SD 
p-value 
2-amino 
Day 1 to Day 2 
1.44 
11.94 
0.6474 
2-amino 
Day 2 to Day 7 
1.44 
9.32 
0.5585 
2-amino 
Day 1 to Day 7 
2.88 
12.91 
0.4017 
3-MT 
Day 1 to Day 2 
-8.47 
23.61 
0.1862 
3-MT 
Day 2 to Day 7 
-3.66 
20.89 
0.5080 
3-MT 
Day 1 to Day 7 
-12.14 
29.06 
0.1281 
5-HT 
Day 1 to Day 2 
4.37 
37.33 
0.6569 
5-HT 
Day 2 to Day 7 
2.47 
68.38 
0.8908 
5-HT 
Day 1 to Day 7 
6.84 
63.59 
0.6832 
5-HT/DA 
Day 1 to Day 2 
-0.18 
0.83 
0.4202 
5-HT/DA 
Day 2 to Day 7 
-0.06 
0.68 
0.7305 
5-HT/DA 
Day 1 to Day 7 
-0.24 
0.89 
0.3117 
5-HTP 
Day 1 to Day 2 
10.48 
72.69 
0.5852 
5-HTP 
Day 2 to Day 7 
-12.80 
74.71 
0.5176 
5-HTP 
Day 1 to Day 7 
-2.32 
31.99 
0.7830 
Ala 
Day 1 to Day 2 
-20.17 
36.89 
0.0526 
Ala 
Day 2 to Day 7 
22.04 
55.11 
0.1437 
Ala 
Day 1 to Day 7 
1.87 
64.03 
0.9115 
Arg 
Day 1 to Day 2 
-0.84 
2.32 
0.1850 
Arg 
Day 2 to Day 7 
2.22 
5.27 
0.1246 
Arg 
Day 1 to Day 7 
1.39 
6.37 
0.4138 
Asn 
Day 1 to Day 2 
-2.51 
10.74 
0.3802 


--- Page 46 ---
Asn 
Day 2 to Day 7 
0.49 
14.07 
0.8942 
Asn 
Day 1 to Day 7 
-2.02 
16.81 
0.6488 
Asp 
Day 1 to Day 2 
0.30 
2.31 
0.6174 
Asp 
Day 2 to Day 7 
-0.41 
2.88 
0.5869 
Asp 
Day 1 to Day 7 
-0.11 
2.84 
0.8830 
Bala 
Day 1 to Day 2 
-11.31 
27.09 
0.1283 
Bala 
Day 2 to Day 7 
4.19 
21.26 
0.4578 
Bala 
Day 1 to Day 7 
-7.12 
33.99 
0.4309 
C-C 
Day 1 to Day 2 
0.20 
8.83 
0.9302 
C-C 
Day 2 to Day 7 
3.94 
14.15 
0.2991 
C-C 
Day 1 to Day 7 
4.14 
11.81 
0.1958 
Car 
Day 1 to Day 2 
-4.41 
14.24 
0.2499 
Car 
Day 2 to Day 7 
-0.15 
4.45 
0.8949 
Car 
Day 1 to Day 7 
-4.57 
13.87 
0.2228 
Cit 
Day 1 to Day 2 
0.14 
1.39 
0.6968 
Cit 
Day 2 to Day 7 
0.09 
1.29 
0.7854 
Cit 
Day 1 to Day 7 
0.24 
1.61 
0.5800 
Cre 
Day 1 to Day 2 
40.33 110.05 
0.1776 
Cre 
Day 2 to Day 7 
-5.67 
94.86 
0.8204 
Cre 
Day 1 to Day 7 
34.67 107.60 
0.2326 
Cys 
Day 1 to Day 2 
9.12 
27.62 
0.2215 
Cys 
Day 2 to Day 7 
-16.07 
23.86 
0.0206 
Cys 
Day 1 to Day 7 
-6.95 
20.99 
0.2205 
Cys/C-c 
Day 1 to Day 2 
0.35 
1.58 
0.4053 
Cys/C-c 
Day 2 to Day 7 
-0.43 
1.77 
0.3677 
Cys/C-c 
Day 1 to Day 7 
-0.07 
0.80 
0.7244 
Cystathion 
Day 1 to Day 2 
0.88 
8.71 
0.7009 
Cystathion 
Day 2 to Day 7 
-1.28 
9.25 
0.5989 
Cystathion 
Day 1 to Day 7 
-0.40 
8.28 
0.8533 
DA 
Day 1 to Day 2 
-3.28 
48.13 
0.7954 
DA 
Day 2 to Day 7 
9.93 
54.17 
0.4893 
DA 
Day 1 to Day 7 
6.65 
65.22 
0.6990 
E 
Day 1 to Day 2 
-2.09 
3.08 
0.0197 
E 
Day 2 to Day 7 
1.59 
2.94 
0.0552 
E 
Day 1 to Day 7 
-0.51 
3.93 
0.6264 
GABA 
Day 1 to Day 2 
-0.54 
1.20 
0.1034 
GABA 
Day 2 to Day 7 
-0.19 
1.20 
0.5558 
GABA 
Day 1 to Day 7 
-0.73 
1.50 
0.0818 
GSH 
Day 1 to Day 2 
0.23 
0.71 
0.2262 
GSH 
Day 2 to Day 7 
0.51 
1.37 
0.1737 
GSH 
Day 1 to Day 7 
0.74 
1.68 
0.1099 


--- Page 47 ---
Gln 
Day 1 to Day 2 
-24.29 
69.86 
0.1996 
Gln 
Day 2 to Day 7 
-2.67 
60.13 
0.8657 
Gln 
Day 1 to Day 7 
-26.96 
86.37 
0.2467 
Glu 
Day 1 to Day 2 
-2.00 
6.71 
0.2674 
Glu 
Day 2 to Day 7 
-3.82 
6.73 
0.0453 
Glu 
Day 1 to Day 7 
-5.82 
10.37 
0.0475 
Gly 
Day 1 to Day 2 
-72.54 117.73 
0.0317 
Gly 
Day 2 to Day 7 
34.67 107.20 
0.2308 
Gly 
Day 1 to Day 7 
-37.87 
83.70 
0.1016 
HCys2 
Day 1 to Day 2 
0.35 
0.55 
0.0296 
HCys2 
Day 2 to Day 7 
-0.08 
0.55 
0.5806 
HCys2 
Day 1 to Day 7 
0.27 
0.79 
0.2125 
HYP 
Day 1 to Day 2 
-0.37 
1.02 
0.1856 
HYP 
Day 2 to Day 7 
0.02 
0.93 
0.9262 
HYP 
Day 1 to Day 7 
-0.34 
1.31 
0.3281 
Hcys 
Day 1 to Day 2 
0.06 
0.68 
0.7225 
Hcys 
Day 2 to Day 7 
0.10 
0.76 
0.6112 
Hcys 
Day 1 to Day 7 
0.17 
0.66 
0.3446 
His 
Day 1 to Day 2 
-46.32 
75.35 
0.0320 
His 
Day 2 to Day 7 
-0.33 
56.38 
0.9824 
His 
Day 1 to Day 7 
-46.64 
49.35 
0.0026 
Hist 
Day 1 to Day 2 
-9.24 
20.20 
0.0981 
Hist 
Day 2 to Day 7 
4.82 
25.30 
0.4724 
Hist 
Day 1 to Day 7 
-4.42 
18.90 
0.3804 
Hlys 
Day 1 to Day 2 
-0.62 
1.36 
0.1000 
Hlys 
Day 2 to Day 7 
-0.18 
0.43 
0.1301 
Hlys 
Day 1 to Day 7 
-0.80 
1.75 
0.0992 
Hser 
Day 1 to Day 2 
-3.10 
8.41 
0.1751 
Hser 
Day 2 to Day 7 
0.60 
8.42 
0.7873 
Hser 
Day 1 to Day 7 
-2.50 
9.34 
0.3169 
Ile 
Day 1 to Day 2 
-2.00 
5.96 
0.2157 
Ile 
Day 2 to Day 7 
-0.80 
6.14 
0.6207 
Ile 
Day 1 to Day 7 
-2.80 
8.50 
0.2232 
LDOPA 
Day 1 to Day 2 
2.01 
11.54 
0.5111 
LDOPA 
Day 2 to Day 7 
-0.52 
9.83 
0.8408 
LDOPA 
Day 1 to Day 7 
1.49 
10.18 
0.5798 
Leu 
Day 1 to Day 2 
-4.84 
7.84 
0.0313 
Leu 
Day 2 to Day 7 
1.97 
8.21 
0.3681 
Leu 
Day 1 to Day 7 
-2.87 
11.54 
0.3515 
Lys 
Day 1 to Day 2 
-8.88 
32.44 
0.3070 
Lys 
Day 2 to Day 7 
1.24 
30.39 
0.8768 


--- Page 48 ---
Lys 
Day 1 to Day 7 
-7.64 
34.89 
0.4106 
ME 
Day 1 to Day 2 
-4.29 
14.51 
0.2718 
ME 
Day 2 to Day 7 
-1.45 
6.17 
0.3775 
ME 
Day 1 to Day 7 
-5.74 
14.29 
0.1421 
Met 
Day 1 to Day 2 
-0.43 
4.04 
0.6863 
Met 
Day 2 to Day 7 
-0.28 
3.88 
0.7816 
Met 
Day 1 to Day 7 
-0.71 
4.61 
0.5582 
NE 
Day 1 to Day 2 
-0.78 
16.15 
0.8544 
NE 
Day 2 to Day 7 
10.50 
44.57 
0.3769 
NE 
Day 1 to Day 7 
9.72 
40.68 
0.3702 
NE/E 
Day 1 to Day 2 
2.92 
6.55 
0.1064 
NE/E 
Day 2 to Day 7 
1.72 
14.81 
0.6605 
NE/E 
Day 1 to Day 7 
4.63 
13.58 
0.2074 
NorM 
Day 1 to Day 2 
0.00 
28.16 
0.9996 
NorM 
Day 2 to Day 7 
-13.06 
23.32 
0.0479 
NorM 
Day 1 to Day 7 
-13.06 
33.37 
0.1519 
Orn 
Day 1 to Day 2 
-3.30 
9.38 
0.1949 
Orn 
Day 2 to Day 7 
1.50 
9.82 
0.5632 
Orn 
Day 1 to Day 7 
-1.80 
7.13 
0.3456 
PEA 
Day 1 to Day 2 
-0.17 
1.16 
0.5730 
PEA 
Day 2 to Day 7 
-0.42 
1.61 
0.3262 
PEA 
Day 1 to Day 7 
-0.59 
1.12 
0.0589 
Phe 
Day 1 to Day 2 
-4.13 
9.28 
0.1067 
Phe 
Day 2 to Day 7 
6.33 
10.94 
0.0418 
Phe 
Day 1 to Day 7 
2.19 
15.37 
0.5889 
Pro 
Day 1 to Day 2 
-2.35 
8.45 
0.2989 
Pro 
Day 2 to Day 7 
0.05 
5.99 
0.9747 
Pro 
Day 1 to Day 7 
-2.30 
8.15 
0.2921 
Ratio 
Day 1 to Day 2 
-0.71 
1.40 
0.0700 
Ratio 
Day 2 to Day 7 
0.46 
1.25 
0.1782 
Ratio 
Day 1 to Day 7 
-0.25 
1.32 
0.4732 
Sar 
Day 1 to Day 2 
-0.22 
6.88 
0.9038 
Sar 
Day 2 to Day 7 
0.22 
3.86 
0.8301 
Sar 
Day 1 to Day 7 
0.00 
5.17 
0.9996 
Ser 
Day 1 to Day 2 
-3.44 
49.51 
0.7915 
Ser 
Day 2 to Day 7 
-5.47 
31.29 
0.5096 
Ser 
Day 1 to Day 7 
-8.91 
38.25 
0.3821 
Thr 
Day 1 to Day 2 
-6.02 
41.35 
0.5819 
Thr 
Day 2 to Day 7 
0.55 
37.91 
0.9563 
Thr 
Day 1 to Day 7 
-5.47 
29.80 
0.4887 
Trp 
Day 1 to Day 2 
6.41 
21.61 
0.2699 


--- Page 49 ---
Trp 
Day 2 to Day 7 
-10.81 
18.55 
0.0406 
Trp 
Day 1 to Day 7 
-4.40 
17.07 
0.3355 
Tryp 
Day 1 to Day 2 
-0.03 
0.15 
0.5022 
Tryp 
Day 2 to Day 7 
0.06 
0.20 
0.2341 
Tryp 
Day 1 to Day 7 
0.04 
0.26 
0.5873 
Tyr 
Day 1 to Day 2 
3.19 
12.77 
0.3503 
Tyr 
Day 2 to Day 7 
-0.75 
12.29 
0.8175 
Tyr 
Day 1 to Day 7 
2.44 
12.23 
0.4527 
Tyra 
Day 1 to Day 2 
-1.04 
3.18 
0.2259 
Tyra 
Day 2 to Day 7 
0.37 
2.36 
0.5546 
Tyra 
Day 1 to Day 7 
-0.67 
2.96 
0.3963 
Val 
Day 1 to Day 2 
-10.85 
24.39 
0.1068 
Val 
Day 2 to Day 7 
7.58 
31.90 
0.3728 
Val 
Day 1 to Day 7 
-3.27 
43.87 
0.7772 
a-amino 
Day 1 to Day 2 
-3.61 
9.26 
0.1534 
a-amino 
Day 2 to Day 7 
-5.29 
7.79 
0.0198 
a-amino 
Day 1 to Day 7 
-8.90 
13.79 
0.0256 
b-aminoiso Day 1 to Day 2 
18.36 177.75 
0.6952 
b-aminoiso Day 2 to Day 7 
-38.68 150.08 
0.3351 
b-aminoiso Day 1 to Day 7 
-20.32 
51.24 
0.1468 
 
 
 
 
 
 
GHK- CU Study – Cortisol and DHEAS 
 
Table 1: Summary statistics for AUC of Cortisol and DHEAS, stratified by assessment time point ........... 49 
Table 2: Change from R1 to R2, R2 to R3 and R1 to R3 .............................................................................. 50 
 
Study Design: Single arm study with 3 assessment time points. 
 
Sample Size:  N=15 
 
Statistical Methods: Cortisol levels were obtained at 8am, 12pm, 4pm, 8pm and 12am. 
DHEAS levels were collected at 8am, 8pm and 12am. The area under the curve (AUC) 
for Cortisol and DHEAS levels over the data collection periods were calculated using the 
trapezoid rule. AUC levels were summarized in terms of means and standard deviations, 
stratified by assessment time point. Changes between assessment time points were 
evaluated using a paired t-test or Wilcoxon signed rank test. 
 
Table 29: Summary statistics for AUC of Cortisol and DHEAS, stratified by assessment time point 


--- Page 50 ---
Marker 
Assessment 
Time point 
Mean 
AUC 
SD 
Cortisol 
R1 (pre-patch) 
109.1 
36.9 
Cortisol 
R2 
120.6 
28.4 
Cortisol 
R3 
141.7 
76.4 
DHEAS 
R1 (pre-patch) 
178,2 
154,5 
DHEAS 
R2 
180.7 
117.7 
DHEAS 
R3 
291.0 
378.4 
 
 
 
Table 30: Change from R1 to R2, R2 to R3 and R1 to R3 
Marker 
Change 
Mean 
Change in 
AUC 
SD 
p-value 
Cortisol 
R1 to R2 
11.5 
41.9 
0.7615 
 
R2 to R3 
21.1 
90.2 
0.9780 
 
R1 to R3 
32.6 
87.9 
0.2769 
DHEAS 
R1 to R2 
1.2 
97.7 
0.7148 
 
R2 to R3 
111.6 
362.6 
0.7609 
 
R1 to R3 
112.8 
345.7 
0.5016 
 
 
There are no significant changes in Cortisol or DHEAS levels between assessment time 
points.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


--- Page 51 ---
Appendix B: General Study Protocol 
 
 
1. IRB submission 
2. IRB approval 
3. Distribute flyers and email announcements 
4. Begin recruiting as people call in for study information 
5. Schedule participants that meet inclusion and exclusion criterion 
6. Consent a participant and administer baseline test and baseline physio test 
7. Schedule participant for next am and issue one patch for application 8 am. 
8. Call participant to confirm patch application. 
9. Meet participant at laboratory for initial testing at 9:00 am 
a. First salivary swab 
b. Physio suite testing 
c. Memory test part 1 
d. 10 am urine  
e. Questionnaires 
f. Memory test part 2 
10. Schedule for next day and issue salivary kit and patch for next morning 
11. Call and confirm salivary test and patch application 8 am 
12. Repeat 9a-f 
13. Issue salivary kit and 5 patches and remind participant to freeze salivary samples 
or bring them in the next morning if local. 
14. The 6th night of study period, call and remind participant of appointment. Remind 
them to bring salivary kit. 
15. Repeat 9 a-f. Issue new salivary kit. Receive participant’s second salivary kit. 
16. Arrange for participant to deliver salivary kit the next day. 
17. Ship kits and urines received once a week to Sabre Sciences. 
18. Do ongoing data entry of physio data and questionnaire data to maximize study 
turn around. 
19. When study is complete email spreadsheets to statistics analysis. 
20. Receive analysis and submit report. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


--- Page 52 ---
Appendix C: Study Team 
 
Dr. Melinda H. Connor, D.D., Ph.D., AMP, FAM: PI 
Dr. Melinda Connor, has trained as a clinical psychologist, neuropsychologist, 
and is board certified in alternative medicine and a Fellow of the American Alternative 
Medicine Association. Dr. Connor holds an A.A. in Humanities from Harvard University, 
a B.A. in Theatre and English from Wellesley College. Her training includes master’s 
degrees from programs at University of San Francisco and American Public University 
and a Ph.D. in clinical psychology from California Coast University with a one-year 
rotation in neuropsychology. As a National Institutes of Health T-32 post-doctoral fellow, 
Dr. Connor received her training as a research scientist at the University of Arizona under 
Dr. Andrew Weil and Dr. Iris Bell and was director of the Optimal Healing Research 
Program at the Laboratory for Advances in Consciousness and Health under Dr. Gary E. 
Schwartz. Dr. Connor is currently the CEO of Earthsongs Holistic Consulting and holds 
faculty positions at several universities.  Dr. Connor has a research laboratory in Arizona 
and is the author of ten books. 
 
Dr. Caitlin C. Connor, MAcOM, DAOM: Co-I 
Dr. Caitlin Connor holds a bachelors degree from Mount Holyoke College with a 
dual focus in political science and anthropology, a master’s degree in acupuncture and 
oriental medicine from Arizona School of Acupuncture and Oriental Medicine and a 
doctorate in Acupuncture and Oriental Medicine from California Institute for Integral 
Studies/American College of Traditional Chinese Medicine. Dr. Connor’s research 
training began in high school in a special program at the University of Arizona where she 
was mentored by Dr. Gary Schwartz at the Laboratory for the Advancement in 
Consciousness and Health in the Department of Psychology. Dr. Connor was the 
ISSSEEM 2011 gold medal winner of the Rustum Roy Emerging Scientist Award for 
undergraduates, a 2014 Bernard Grad Emerging Scientist silver medal winner for 
graduate students and a 2018 Patricia Norris Award gold medal winner. Dr. Connor is 
currently doing additional research training at University of Oxford, UK and commuting 
between countries.  
 
Dr. Naran Gombosuren, Ph.D.: Metabolic Analysis 
Dr. Naran Gombosuren, Ph.D., is technical director and lead research scientist at Sabre 
Sciences Laboratory/EndoSciences in Carlesbad, CA. Originally from Mongolia and 
trainned in Hungary, Dr. Gomobsuren received her Ph.D. from Eotvos University in 
Budepest. Dr. Gombosuren has worked with such prestigious groups as Scripps Research 
Institute and Sanford-Burnham Prebys Medical Discovery Institute. A specialist in 
complex metabolic process Dr. Gombosuren has participated in studies with topics 
ranging from virology to gut-brain interactions. 
 
Dr. Jens Eickhoff, Ph.D: Statistics 
Dr. Jens Eickhoff earned his Ph.D. in 2002 in statistics from Iowa State University. He is 
a senior scientist in the Department of Biostatistics and Medical Informatics at University 
of Wisconsin Madison where he teaches Biostatistics. A specialist in complex research 
statistics he has participated in studies ranging from oncology to endocrinology and 
published extensively on bio-statistical modeling. 


